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Abstract 
Prior to beta-amyloid (Aβ) protein accumulation into plaques in Alzheimer’s disease 
(AD), neuroinflammation and oxidative stress have been shown to contribute to early 
cognitive decline. These cellular pathologies are coincident in stroke, which is considered 
a risk factor for AD. This study investigated the co-morbid effects of AD and stroke on 
behavioural and cellular pathology in two rodent models. Motor function, memory and 
microglial neuroinflammation were investigated in a stroke and Aβ injection model and 
mutant human amyloid precursor protein (APP) transgenic model with stroke. Injections 
of endothelin-1 into the right striatum were used to model stroke and AD was modelled 
through either intracerebroventricular Aβ25-35 injections or a transgenic rat that 
overproduces a mutated form of human APP. Furthermore, the effectiveness of a targeted 
antioxidant therapy (CAT-SKL) was investigated in the stroke and Aβ injection model. 
Memory deficits were present in both co-morbid conditions and CAT-SKL was able to 
ameliorate the memory deficit in the stroke and Aβ injection model. In the transgenic 
model, the co-morbid condition resulted in gait alterations. Levels of activated microglia 
in the infarct region were increased in the transgenic co-morbid condition. Exacerbation 
of activated microglia in the basal forebrain of the co-morbid stroke and Aβ injection 
model was observed and was attenuated by CAT-SKL treatment. The findings of this 
study demonstrate the co-morbid effects in the pathogenesis of AD pathologies. This 
study suggests that neuroinflammation plays a crucial role in AD and use of targeted 
therapies, such as CAT-SKL, should be the focus of future research on therapeutic 
strategies for AD. 
Keywords: Alzheimer’s disease, stroke, co-morbid, Aβ, neuroinflammation, oxidative 
stress, catalase 
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Chapter 1: 
Introduction
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1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a neurodegenerative disease that results in the 
deterioration of the brain, particularly forebrain areas associated with cognition. On a 
cellular level, amyloid plaques and neurofibrillary tangles (NFTs) in the brain are 
classically thought to accompany the behavioural impairments associated with AD. These 
characteristic behavioural impairments include memory loss, mood instability and 
learning impairments (Auld et al., 2002; Selkoe, 2001; Querfurth and LaFerla, 2010). AD 
is the most prevalent form of dementia in the elderly population (65+ years of age) 
affecting approximately 747,000 Canadians. By the year 2031, it is estimated that there 
will be approximately 1.4 million people in Canada living with AD and experiencing the 
life-changing symptoms involved (Alzheimer Society Canada, 2012). This drastic 
increase is partially due to the increasing number of people over 65 years of age and an 
increase in the lifespan of humans (Norris, 2007). The number of people living with AD 
and the severity of the disease emphasizes the importance of fully understanding the 
pathogenesis of AD and developing treatment and prevention strategies for those affected 
and at risk for developing the disease. 
While there has been no consensus on the cause of AD, there has been major 
speculation about the stages and progression of the disease. The hallmark histopathology 
of the disease is the presence of insoluble extracellular amyloid plaques in the brain. The 
amyloid-beta protein (Aβ) that deposits as plaques is a product of the amyloid precursor 
protein (APP), a single transmembrane polypeptide (Citron, 2010; De Strooper et al., 
2003; Selkoe, 2001; Querfurth and LaFerla, 2010). APP has been implicated in cell-to-
cell interaction and adhesion, but its main physiological function is widely unknown 
(Nalivaeva and Turner, 2013; Schubert et al., 1989; Qiu et al., 1995). As APP is 
translocated to the endoplasmic reticulum for secretion after synthesis, the protein is 
subject to various post-translational modifications. In particular, APP can be processed 
through an amyloidogenic or nonamyloidogenic pathway (Selkoe, 2001; Querfurth and 
LaFerla, 2010).  
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In the amyloidogenic pathway, APP is sequentially cleaved by β-secretase and γ-
secretase to create Aβ (Selkoe, 2001; Querfurth and LaFerla, 2010). Beta-site amyloid 
precursor protein-cleaving enzyme (BACE1) is the active component of β-secretase (Cai 
et al., 2001), cleaving APP into a smaller β-APPs fragment and the C99 transmembrane 
carboxyl-terminal domain of APP (Seubert et al., 1993). Following cleavage by β-
secretase, the membrane-bound C99 is cleaved by γ-secretase, which contains presenilin-
1 (PS1) or presenilin-2 (PS2) at its catalytic core (De Strooper et al., 2003; Xia et al., 
1997; Xia et al., 1998). Cleavage by γ-secretase can occur at multiple sites, releasing a 
37-43 Aβ peptide (Haass and Selkoe, 1993; Shoji et al., 1992).  
The predominant form of Aβ produced in the brain is Aβ40, but Aβ42 is considered 
the most susceptible to aggregation and plaque formation (Jarrett et al., 1993; Walsh and 
Selkoe, 2007; Querfurth and LaFerla, 2010). Once Aβ is produced, it can be cleared from 
the brain through the glymphatic system, which consists of cerebrospinal fluid influx 
around arteries and exit of interstitial fluid along veins in the brain (Xie et al., 2013). An 
imbalance between production and clearance of Aβ in the brain has been proposed as a 
cause for increased Aβ levels (Hardy and Selkoe, 2002; Mawuenyega et al., 2010). If it is 
not cleared, Aβ can self-aggregate creating soluble oligomeric fibrils that eventually 
become insoluble aggregates or plaques (Selkoe, 2001; Querfurth and LaFerla, 2010). 
These plaques can lead to neuroinflammation, oxidative stress and synaptic dysfunction 
that result in the characteristic memory loss and learning impairments in AD (Hsiao et al., 
1996; Palop and Mucke, 2010; Selkoe, 2002). This entire process is termed the “amyloid 
cascade hypothesis” and is considered an initiating factor of AD (Hardy and Higgins, 
1992; Karran et al., 2011).  
The inextricable link between AD and Aβ has lead to a substantial amount of 
research on the involvement of Aβ in the disease process. This research has resulted in an 
alteration to the original amyloid cascade hypothesis, since evidence has suggested that 
plaques are not always indicative of AD. There is clinical evidence of cognitively intact 
elderly individuals with Aβ accumulation, questioning the role of Aβ and plaques in the 
disease process (Aizenstein et al., 2008; Dickson et al., 1992). Alternatively, cognitive 
deficits indicative of AD can present prior to deposition of Aβ into plaques (LaFerla et 
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al., 2007; Selkoe, 2001). Further investigation uncovered that the level of soluble Aβ in 
the brain correlated to the level of cognitive decline (Lue et al., 1999; McLean et al., 
1999; Oda et al., 1995). The contradictory results lead to the amyloid cascade hypothesis 
expanding to include soluble Aβ and amyloid-derived diffusible ligands (ADDL), while 
also decreasing confidence in Aβ plaques being the sole cause of AD (Krafft and Klein, 
2010). 
Although Aβ still remains a fundamental feature in the pathophysiology of AD, 
another proteinopathy implicated in the disease process involves tau protein. Tau is 
involved in microtubule stabilization, but can aggregate and become toxic when it is 
abnormally phosphorylated (Kosik et al., 1986; Trojanowski and Lee, 1995). These 
intracellular aggregates of abnormally phosphorylated tau are referred to as NFTs and are 
indicative of a progressed disease state. Previously, it has been shown that AD patients 
with NFTs tended to display a more severe cognitive decline compared to their 
counterparts devoid of NFTs (Terry et al., 1987). Furthermore, NFTs are hypothesized to 
be a response to the accumulation of Aβ in the brain and studies propose that without the 
presence of Aβ, NFTs do not result in AD (Götz et al., 2001; Selkoe, 2001; Terry et al., 
1987; Querfurth and LaFerla, 2010). This is highly suggestive that tau is not the leading 
cause of AD and rather these two proteins interact in progressed disease states. 
While proteinopathies are important in disease progression, other cellular 
pathologies have also been implicated in the pathogenesis of AD. There is a growing 
body of evidence supporting a major link between inflammation and AD (Akiyama et al., 
2000; Rojo et al., 2008; Wyss-Coray and Mucke, 2002). Furthermore, oxidative stress 
caused by increased levels of reactive oxygen species (ROS) has also been implicated 
(Butterfield et al., 2001; Markesbery and Carney, 1999; Sagara et al., 1998). These 
cellular pathologies have both been involved in the aberrant synaptic transmission 
involving dysfunction in neurotransmitter release and alterations in receptor distribution 
in AD (Butterfield et al., 2001; Masliah et al., 2001; Shankar et al., 2007; Wang et al., 
2000; Wyss-Coray and Mucke, 2002). Newly emerging evidence investigating the effect 
of other diseases on the pathogenesis of AD has shown a link between insulin and the 
development of AD, suggesting there is a relationship between diabetes and AD 
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(Arvanitakis et al., 2004; Craft et al., 1998; Messier et al., 2005; Stewart and Liolitsa, 
1999). More importantly, there are a substantial number of clinical studies demonstrating 
a synergism between vascular insults (i.e. stroke, hypertension) and AD (Kokmen et al., 
1996; Snowdon et al., 1997; Snyder et al., 2015). While evidence converges at certain 
aspects, no consensus on the crucial factors involved in the early stages of the disease has 
been achieved and thus research should continue to investigate all aspects proposed thus 
far, including risk factors, Aβ, tau, inflammation, oxidative stress and synaptic 
dysfunction (Butterfield et al., 2001; Akiyama et al., 2000; Selkoe 2001; Querfurth and 
LaFerla, 2010).  
1.2 Risk Factors for AD 
AD is classified into two different forms, sporadic late-onset (> 60 years old) AD 
or familial early-onset (< 60 years old) AD (FAD). Sporadic AD accounts for the 
majority of individuals diagnosed with the disease with roughly 1-10% of cases 
presenting as FAD (Campion et al., 1999; Selkoe, 2001). Extensive research has 
uncovered the most common autosomal dominant genetic predispositions to FAD. These 
include missense mutations in APP and presenilin (Bertram et al., 2010; Goate et al., 
1991; Sherrington et al., 1995). Direct alterations in the APP gene are linked to AD in 
very few cases, but there is strong evidence that APP genetic variations are the driving 
force in the interaction between Down syndrome and AD. Patients with Down syndrome 
invariably develop early-onset AD from the overexpression of APP and subsequent 
elevated levels of Aβ40 and Aβ42 due to the duplication of chromosome 21, which 
contains the APP gene (Walsh and Selkoe, 2007; Tokuda et al., 1997). Contrary to 
mutations in APP, mutations in presenilin are considered the most predominant genetic 
predisposition in FAD (Bertram et al., 2010; Selkoe, 2001). Mutations in the presenilin 
proteins result in a drastic increase in Aβ42 plaques in comparison to sporadic forms of 
AD (Lemere et al., 1996; Mann et al., 1996). The development of this phenotype is 
attributable to differential γ-secretase activity (Xia et al. 1997). As with Down syndrome, 
individuals with autosomal dominant mutations in presenilin invariably develop FAD 
(Bertram et al., 2010; Selkoe, 2001). 
  6 
Whilst only FAD is considered genetically driven, it has been suggested that 
sporadic forms may originate from genetic differences. Apolipoprotein E (ApoE) can 
occur in three different isoforms depending on the allele in the genome and each isoform 
has distinct functions in the brain (Huang and Mucke, 2012). The presence of an ε4 allele 
in ApoE over an ε2 or ε3 allele increases the probability of developing AD (Corder et al., 
1993; Saunders et al., 1993; Strittmatter et al., 1993). ApoE4 (ε4 allele) has been largely 
implicated with increased Aβ accumulation through decreased clearance of Aβ 
(Castellano et al., 2011; Kim et al., 2009). However, the presence of the ε4 allele does not 
guarantee an eventual AD diagnosis and thus it is not considered the singular genetic 
cause for sporadic forms of the disease (Ringman et al., 2014; Selkoe, 2001). 
Aging remains the most crucial risk factor in the development of sporadic AD. 
While aging alone is not necessarily responsible for disease development, cellular factors 
undergo changes due to age and contribute to the clinical manifestations of AD. For 
example, there is an increase in the levels of ROS, inflammation, protein misfolding and 
aberrant synaptic transmission that occur as a result of age (Godbout and Johnson, 2009; 
Morimoto and Cuervo, 2014; Zhang et al., 2015). Coincidently, all of these factors are 
inextricably linked to the pathophysiology of AD (Butterfield et al., 2001; Huang and 
Mucke, 2012; Wyss-coray and Mucke, 2002). In addition to age, there are also other 
numerous risk factors that increase an individual’s probability of developing AD. Some 
risk factors identified have fallen under the diagnosis of metabolic syndrome, where 
diabetes and obesity have been largely implicated as risk factors for AD (Arvanitakis et 
al., 2004; Messier et al., 2005; Stewart and Liolitsa, 1999). Furthermore, vascular 
conditions are considered highly important AD risk factors, as there have been numerous 
indications of their role in the development of the disease. The most common vascular 
risk factors include hypertension, atherosclerosis and stroke (Altman and Rutledge, 2010; 
Cechetto et al., 2008; Snyder et al., 2015) with substantial clinical evidence that 
implicates stroke as one of the leading vascular risk factors for AD (Kalaria, 2000; 
Snowdon et al., 1997; Vermeer et al., 2007). 
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1.3 Stroke 
Stroke is defined as an alteration in blood flow to the brain resulting in a 
permanent loss of brain function. There are approximately 315,000 people in Canada 
living with the effects of stroke (Public Health Agency of Canada, 2011). Much like AD, 
stroke is an age-related condition most common in people over the age of 70. However, 
occurrences also appear in younger (< 65 years old) individuals (Public Health Agency of 
Canada, 2011). The two major categories of stroke are ischemic or haemorrhagic strokes. 
The latter is a result of a ruptured blood vessel that leads to uncontrollable bleeding in the 
brain (Lakhan et al., 2009). Arteries that supply oxygenated blood to the brain can also 
become blocked by debris or accumulation of lipids in the vessel. The clot formed in the 
arteries blocks blood supply to its downstream target in the brain resulting in an ischemic 
stroke. Majority of strokes manifest as ischemic strokes and range in severity (Lakhan et 
al., 2009). While every stroke causes tissue damage, longer-lasting ischemic blockages 
present differently than transient ischemic attacks (TIA) that typically only last one to 
five minutes. These are considered transient because the blockage dissipates and blood 
flow is recovered to the brain, which is not the case for other ischemic blockages that 
require medical intervention to recover blood flow (Easton et al., 2009). TIAs are 
considered “mini-stokes” in comparison to non-transient ischemic blockages, but are still 
an extremely serious occurrence, as it can indicate future, more severe strokes (Vermeer 
et al., 2002). Nevertheless, all forms of ischemic strokes are implicated as major risk 
factors for AD and are a very common co-morbidity with AD. (Arvanitakis et al., 2011; 
Cechetto et al., 2008; Kalaria, 2000).  
1.4 Stroke and AD 
Compared to patients without stroke, ischemic stroke patients have a higher 
prevalence of dementia (Tatemichi et al., 1992) and it is predicted that approximately 
30% of AD patients have accompanying ischemic strokes (Kalaria, 2000). A point of 
interaction between stroke and AD involves ApoE4. Carriers of the ε4 allele are more 
likely to develop atherosclerosis and other vascular complications (Mahley and Huang, 
1999; Olichney et al., 2000; Prasher et al., 2008). Moreover, incident of stroke increases 
the risk of developing AD five-fold for those that are ε4 allele carriers compared to non-
  8 
carriers (Johnston et al., 2000) and over 60% of patients with combined vascular disease 
and AD carry at least one ε4 allele (Hofman et al., 1997; Kalaria, 2000). In addition to 
ApoE4 genetic synergism, stroke results in cellular pathologies that are largely implicated 
in AD, such as, inflammation, oxidative stress and neurodegeneration (Allen and 
Bayraktutan, 2009; Lakhan et al., 2009; Markesbery and Carney, 1999; Wyss-Coray, 
2006). The overlap in cellular pathology suggests that these are potential points of 
interaction contributing to the relationship between stroke as a risk factor for AD.  
Stroke can also exacerbate pre-existing dementias. In the breakthrough Nun study 
by Snowdon et al. (1997), the presence of stroke greatly increased the severity of AD in 
comparison to those individuals with AD alone. Moreover, these strokes were lacunar-
type strokes, affecting subcortical areas of the brain (Snowdon et al., 1997). This lead to 
research that provided evidence that APP expression, Aβ accumulation, increased 
inflammation and larger infarct volumes are found in co-morbid animal models of AD 
and stroke (Amtul et al., 2014; Whitehead et al., 2005b; Whitehead et al., 2007). It has 
also been reported that APP and Aβ appears in the penumbra following stroke injury in 
animal models (Hiltunen et al., 2009; Shi et al., 2000). Clinical evidence that elderly 
patients with poor cognitive function are at an increased risk for developing stroke 
(Ferrucci et al, 1996; Gale et al., 1996) further supports the relationship between stroke 
and AD. The substantial amount of evidence available suggests that there is a crucial 
interaction between stroke and AD and it is vital that these two pathologies be further 
researched in co-morbid models to better understand the cellular mechanisms involved.  
1.5 Neuroinflammation 
The relationship between inflammation and AD involves propagation of pro-
inflammatory mediators and increased inflammation resulting in increased Aβ production 
(Akiyama et al., 2000; Wyss-Coray and Mucke, 2002). Similar to AD, stroke generates a 
significant amount of inflammation in the brain in response to ischemic injury (Lakhan et 
al., 2009; Wang et al., 2007). This relationship between inflammation and AD and stroke 
suggests that increased inflammation may be a point of synergy between these two 
diseases. Neuroinflammation is mediated by microglia, the macrophages of the brain, and 
astrocytes, the glial cells of the brain (Ousman and Kubes, 2012; Wyss-Coray and 
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Mucke, 2002). Each of these cell types perform different roles in the brain, but both are 
important with regards to neuroinflammation due to their release of pro-inflammatory 
molecules (Akiyama et al., 2000, Rojo et al., 2008; Wyss-Coray, 2006). Microglia are at 
the core of mediating the neuroinflammatory response initiated by foreign pathogens in 
the brain (Latta et al., 2014). Resting state microglia have extended ramified processes 
that can retract resulting in an “amoeboid” shape. The retraction of these processes occurs 
upon detection of a foreign pathogen and the resultant microglia form is deemed 
activated (Lynch, 2009). Activated microglia present a very different molecular and 
biochemical profile, where increased release of chemokines and cytokines and expression 
of major histocompatibility complex II (MHCII) are a few marked differences between 
activated and resting microglia (Akiyama et al., 2000; Luber-Narod and Rogers, 1988, 
Wang et al., 2007). A major role of activated microglia is to phagocytose debris and 
foreign pathogens in the brain to avoid further damage caused by these invaders (Ousman 
and Kubes, 2012). Furthermore, microglia are initiators in the post-insult repair process 
(Ousman and Kubes, 2012; Wang et al., 2007). While, these are highly beneficial defense 
mechanisms, often in disease states the attenuation of this microglial inflammation is not 
balanced with propagation, leading to the persistence of activated microglia and eventual 
development of toxic chronic inflammation (Heneka et al., 2015; Lee et al., 2010; Tuppo 
and Arias, 2005).  
Masses of microglia have been found at sites of Aβ aggregation clinically (Haga 
et al., 1989; Lue et al, 1996) and experimentally (Leon et al., 2010; Liu et al., 2008), 
implicating a signalling interaction between Aβ and microglia. This has been attributed to 
various mechanisms involving direct contact and distant signalling. The latter involves 
microglia being attracted to Aβ-rich areas of the brain as a result of the chemotactic 
signalling produced by Aβ itself (Akiyama et al., 2000). The former involves Aβ directly 
contacting and activating microglia through binding to RAGE (receptor for advanced 
glycation end products), CD36 (cluster differentiation 36), TLR4 (toll-like receptor 4) 
and TLR6 (toll-like receptor 6) on microglia (El Khoury et al., 2003; Stewart et al., 2010; 
Yan et al., 1999). This interaction can initiate the release of pro-inflammatory signals, 
such as interleukin-1, interleukin-6 and tumour necrosis factor-α, further propagating 
microglial infiltration and activation (Akiyama et al., 2000; Campbell et al., 1998; Rojo 
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et al., 2008). There is also evidence in animal models that some of these pro-
inflammatory signals precede Aβ deposition (Ferretti and Cuello, 2011; Grammas, 2011), 
implicating neuroinflammation in the early stages of disease progression. This prolonged 
activation of microglia due to sustained abnormal Aβ accumulation and increasing levels 
of pro-inflammatory signals is thought to give rise to the pathological chronic 
inflammation in AD (Heneka et al., 2015; Latta et al., 2014; Wyss-Coray, 2006). 
Neuroinflammation resulting from stroke also results in microglia entering a self-
propagating cycle that can become neurotoxic. Upon ischemic injury, brain tissue 
undergoes cell death through both apoptosis and necrosis, which in turn triggers a 
pronounced inflammatory response (Lakhan et al., 2009; Wang et al, 2007). Microglia 
infiltrate the ischemic area where they become activated due to the cellular debris and 
neurotoxic factors released as a result of the stroke. This leads to drastic alterations in the 
release patterns of interleukin-1, interleukin-6 and tumour necrosis factor-α, which have 
been thought to have a cytotoxic effect in stroke (Lakhan et al., 2009; Yenari et al., 
2010). Furthermore, it has been demonstrated clinically (Weinstein et al., 2010) and 
experimentally (Ekdahl et al., 2009) that increased levels of activated microglia can 
persist for long periods of time after stroke. This relationship alone can become 
extremely damaging in stroke, but it becomes additive with the pathogenic inflammation 
resulting from AD. For example, increased volume of microglia within the infarct region 
and the hippocampus has been demonstrated in a co-morbid animal model of stroke and 
AD (Amtul et al., 2014; Whitehead et al., 2005b; Whitehead et al., 2007), suggesting that 
microglia may contribute to the exacerbated disease progression in the early stages of the 
co-morbid condition. 
1.6 Oxidative Stress and Antioxidants 
There is increasing evidence connecting oxidative stress to the pathogenesis of 
AD (Butterfield et al., 2001; Hensley et al., 1995; Markesbery and Carney, 1999), as well 
as stroke (Allen and Bayraktutan, 2009, Kontos, 2001). ROS are small oxygen-containing 
molecules with an unpaired electron that can be damaging to cells, such as the hydroxyl 
radical (OH) and superoxide radical (O2–). These molecules are by-products of 
mitochondrial and peroxisomal reactions and are released from activated microglia 
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(Markesbery and Carney, 1999; Moldovan and Moldovan, 2004; Yenari et al., 2010). 
While these molecules are often implicated as neurotoxic molecules, they are extremely 
important in microglial function, cell signalling and synaptic plasticity (Nathan, 2003; 
Paula-lima et al., 2014; Yenari et al., 2010). Antioxidant enzymes and molecules control 
the levels of ROS by converting them into neutral molecules, preventing their 
accumulation.  
Key antioxidant mechanisms activated in the brain include the enzymes 
glutathione peroxidase, superoxide dismutase (SOD) and catalase. Additionally, non-
enzymatic antioxidants include glutathione and nicotinamide adenine dinucleotide 
phosphate (NADPH) molecules (Meraz-Ríos et al., 2014; Moldovan and Moldovan, 
2004). In normal cellular functioning, mitochondria produce O2– during the reduction of 
oxygen to water in aerobic respiration and also produce hydrogen peroxide (H2O2) as a 
by-product (Coyle and Puttfarcken, 1993; Moldovan and Moldovan, 2004). Another large 
source of ROS is the peroxisome, which produces H2O2 during the β-oxidation of fatty 
acids (Moldovan and Moldovan, 2004; Terlecky and Koepke, 2007). While H2O2 is not a 
considered a free radical, its oxidant properties, ability to diffuse within and between 
cells and yield the extremely toxic OH through Fenton and Haber-Weiss reactions 
implicates it as a ROS (Christen, 2000; Dasuri et al., 2013; Markesbery and Carney, 
1999). One of the main antioxidant enzymes in the mitochondria is SOD, which provides 
protection against increasing levels of O2– (Coyle and Puttfarcken, 1993; Moldovan and 
Moldovan, 2004). Furthermore, catalase is specifically targeted to the peroxisome to 
enzymatically breakdown H2O2 into water and oxygen (Terlecky et al., 2006). When the 
production of ROS outweighs the antioxidant activity of these enzymes, oxidative stress 
can occur and ROS become neurotoxic leading to oxidation of proteins, DNA, lipids and 
eventually cell death (Giordano and Terlecky, 2012; Zhang et al., 2015). 
The brain is especially vulnerable to ROS due to its rich lipid content, lack of 
antioxidants compared to other organs and dependence on oxygen to produce energy 
(Coyle and Puttfarcken, 1993; Markesbery and Carney, 1999; Massaad, 2011). Altered 
ROS-producing energy metabolism in the mitochondria regularly occurs in AD brains, as 
well as those at high risk for developing the disease (Aliev et al., 2003; Beal, 1995; 
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Schuessel et al., 2006). Evidence has also suggested that ROS may be involved in the 
early stages of the disease, as increased oxidative damage has been demonstrated in AD 
animal models (Resende et al., 2008; Schuessel et al., 2006) and Down syndrome patients 
(Nunomura et al., 2000) prior to Aβ accumulation. Furthermore, Aβ is linked to oxidative 
stress, whereby Aβ directly produces ROS (Harris et al., 1995; Hensley et al., 1994; 
Lauderback et al.; 2002; Tabner et al., 2005). For example, there is evidence that aging 
and AD brains accumulate abnormal levels of iron (Fe3+) and Aβ can reduce Fe3+ to Fe2+ 
consequently producing H2O2 (Deibel et al., 1996; Perry et al., 2002; Rottkamp et al., 
2001). This reduction contributes further to oxidative stress, as the Fenton reaction 
produces OH from H2O2 reacting with Fe2+ (Jomova et al., 2010). Moreover, Aβ 
indirectly produces ROS through activated microglia that release ROS upon activation as 
part of their opsonizing methods (Akiyama et al., 2000; Lue et al., 1996). The presence of 
ROS further exacerbates the microglial neuroinflammation in AD, as ROS accumulation 
recruits activated microglia (Heneka et al., 2015). Examination of antioxidant 
mechanisms in human AD brains has demonstrated a decrease in SOD and catalase 
(Gsell et al., 1995; Venkateshappa et al., 2012), implicating alterations in antioxidant 
defence. The increased production of ROS and decreased antioxidant capacity suggests 
that the imbalance of antioxidant defense and increased production of ROS largely 
contributes to oxidative stress in AD.  
A major factor in the pathogenesis of stroke involves oxidative stress, where the 
energy deprivation that occurs immediately following ischemic stroke results in ROS-
induced oxidative damage (Allen and Bayraktutan, 2009; Cuzzocrea et al., 2001; Saeed et 
al., 2007). A release of glutamate post-stroke activates α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, which results in downstream production of 
O2– (Allen and Bayraktutan, 2009; Kontos, 2001). Furthermore, disturbances in 
mitochondrial electron transport increase the production of O2– during ischemia and 
upon reoxygenation after stroke (Allen and Bayraktutan, 2009; Sims and Anderson, 
2002). The increased levels of O2– can further perpetuate oxidative stress, as 
accumulation of lactic acid in neurons post-stroke enhances conversion of O2– to H2O2 
(Saeed et al., 2007). Increased availability of free Fe3+ (Selim and Ratan, 2004) and 
increased presence of microglia (Yenari et al., 2010) also contribute to levels of ROS in 
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stroke. The overlap of the importance of oxidative stress alterations in both stroke and 
AD coupled with the vulnerability of the brain reinforces the contribution of oxidative 
stress in the development and progression of neurodegeneration in the co-morbid 
condition of stroke and AD.  
1.7 Catalase 
An age-related decrease in catalase levels in the brain has been demonstrated both 
clinically (Venkateshappa et al., 2012) and experimentally (Alper et al., 1998), thus 
contributing to the oxidative stress observed in AD and stroke. Catalase is directly 
targeted to the peroxisome through a KANL (lysine-alanine-asparagine-leucine) protein 
targeting sequence (Terlecky et al., 2006). The KANL protein targeting sequence is 
different from other peroxisomal enzymes that have a SKL (serine-lysine-leucine) 
sequence (Terlecky et al., 2006). The efficiency of the carboxy-terminus KANL targeting 
sequence significantly decreases with increasing age resulting in a mislocalization of 
catalase to the cytoplasm (Koepke et al., 2007; Legakis et al., 2002). This mislocalization 
results in decreased digestion of H2O2 leading to its accumulation in cells (Koepke et al., 
2007).  
Due to the implications of the inefficient KANL protein targeting sequence, a 
genetically engineered form of catalase with the more efficient SKL (serine-lysine-
leucine) protein targeting signal (CAT-SKL) was developed to better target catalase to 
the peroxisome (Giordano and Terlecky, 2012). Koepke et al. (2007) demonstrated 
increased import of CAT-SKL compared to catalase with its canonical KANL sequence 
in senescent cells. Furthermore, increased localization of CAT-SKL to the peroxisome 
and subsequent decrease in H2O2 and senescence marker β-galactosidase was observed in 
these cells (Koepke et al., 2007). The use of CAT-SKL in cultured hypocatalasemic 
fibroblasts demonstrated restoration of catalase levels and decreases in H2O2 (Wood et 
al., 2006). Additionally, CAT-SKL has been shown to be effective in protecting cultured 
myocytes against hypoxia-reoxygenation and ischemia-reperfusion injury (Undyala et al., 
2011) and reducing tumour necrosis factor-α in cultured human keratinocytes (Young et 
al., 2008). The evidence supporting the anti-inflammatory and antioxidant properties of 
CAT-SKL lead to the investigation of the effect of CAT-SKL on Aβ toxicity. Giordano et 
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al. (2014) demonstrated that treatment of CAT-SKL prior and subsequent to ADDL 
administration increased cultured primary cortical and hippocampal neuron viability and 
decreased neurite degeneration. Additionally, treatment with CAT-SKL in a rodent model 
of Aβ toxicity resulted in attenuation of Aβ-induced memory deficits, neuroinflammation 
and cholinergic neuron loss (Nell, 2013).  
It has been previously demonstrated that there is a relationship between 
endogenous catalase and Aβ. For example, there has been a direct interaction of Aβ and 
catalase observed in cell cultures, whereby catalase directly binds Aβ resulting in the 
deactivation of catalase and subsequent increase in H2O2 (Habib et al., 2010; Milton, 
1999) and the treatment of cell cultures with catalase has been demonstrated to protect 
cells against Aβ toxicity (Behl et al., 1994; Manelli and Puttfarcken, 1995). Furthermore, 
investigation of brains from AD patients demonstrated the presence of catalase around 
senile plaques (Pappolla et al., 1992). These studies coupled with the pathogenic role of 
ROS in stroke suggests that exacerbation of oxidative stress by age- and Aβ-induced 
changes in catalase may be involved in the early stages of the co-morbid condition of 
stroke and AD and that the use of the targeted antioxidant CAT-SKL may be beneficial 
as a therapeutic agent in the co-morbid condition. 
1.8 Therapeutic Challenges in AD 
A couple of therapeutic approaches for AD have been approved and implemented 
into the treatment regimens for patients. One commonly prescribed treatment for patients 
in all stages of the disease is acetylcholinesterase inhibitors (Donev et al., 2009; Huang 
and Mucke 2012; Selkoe, 2001). These directly target the cholinergic system of the brain, 
which is one of the brain regions largely affected in AD, by decreasing the degradation of 
acetylcholine, subsequently increasing cholinergic transmission (Auld et al., 2002). For 
patients in more advanced stages of AD, the N-methyl-D-aspartate receptor blocker 
memantine is prescribed to reduce glutamate-induced excitotoxicity (Parsons et al., 1999; 
Reisberg et al., 2003). All of these treatments result in improved or stabilized memory 
(Auld et al., 2002; Reisberg et al., 2003), but they are modest at best due to their transient 
effectiveness past one year of repeated use and do not treat the causes of AD, only the 
symptoms (Auld et al., 2002; Petersen et al., 2005).  
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Other therapies being investigated target various aspects of the complex 
pathophysiology of AD, including anti-inflammatories, antioxidants and drugs targeting 
the degradation, production and clearance of Aβ (Cummings, 2004; Heneka et al., 2015; 
Huang and Mucke, 2012). While some anti-Aβ drugs have shown promise, most do not 
transcend further than the first phase of clinical trials (Golde et al., 2011; Huang and 
Mucke, 2012; Mangialasche et al., 2010). Often anti-inflammatory and antioxidant 
treatments are widespread, non-specific mechanisms, which is the case with non-steroidal 
anti-inflammatories (Hensley, 2010; Moore et al., 2010). While these treatments have 
been deemed insufficient in treating AD likely due to their indirect mechanisms, it is also 
highly possible that treatment with antioxidants and anti-inflammatories failed to be 
effective because trials were initiated in patients with progressed AD (Herrup, 2010). It is 
conceivable that treatment in earlier stages of the disease and a more direct or targeted 
approach will lead to successful development of therapies in these categories. 
1.9 Animals Models of Stroke 
Various models have been utilized for researching mechanisms and therapeutic 
approaches for stroke. A standard stroke model in rodents is the middle cerebral artery 
occlusion (MCAO), whereby the middle cerebral artery in the brain is temporarily or 
permanently blocked (Borlongan et al., 2005; Gupta et al., 2002; Wahl et al., 1992). Both 
methods produce different results, with temporary occlusion resulting in reperfusion 
injury in addition to injury from the lack of blood supply (Choi et al., 2012; Li et al., 
2013; Zhang et al, 2013). MCAO usually damages a large portion of the brain 
hemisphere supplied by that artery, causing significant neurodegeneration and 
inflammation in the cortex and a portion of subcortical structures. Another model that 
results in significant brain injury is the common carotid artery occlusion (CCAO), which 
can be accomplished unilaterally or bilaterally in the neck (Choi et al., 2011; Yan et al., 
2007; Zhao et al., 2014). 
While occlusion models are valid stroke models, there is accumulating evidence 
for the synergism of small lacunar or subcortical strokes and AD (Schneider et al., 2007; 
Snowdon et al., 1997; Vermeer et al., 2002). The occlusion stroke models do not mimic 
these small strokes and this lead to the development of a stroke model that targeted 
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subcortical structures. Endothelin-1 (ET-1) is a potent vasoconstrictor capable of 
depleting blood supply through constriction of arteries. While ET-1 occurs naturally in 
the body as a regulator of the cardiovascular system (Yanagisawa et al., 1988), injecting 
various concentrations of ET-1 can produce small strokes in any area in the brain (Clarke 
et al., 2009; Soleman et al., 2010; Weishaupt et al., 2015; Whitehead et al., 2007). This 
ET-1 stroke model has been utilized in various capacities, but most notable have been 
striatal and hippocampal stroke models (Amtul et al., 2014; Cardoso et al., 2013; Clarke 
et al., 2009; Driscoll et al., 2008; McDonald et al., 2008; Whitehead et al., 2005a). The 
ability to target a specific area of the brain using the directed injection of ET-1 renders it 
a strong method for modelling the lacunar infarcts in AD patients. 
1.10 Animals Models of AD 
The challenge with modeling AD is a direct result of its complex pathophysiology 
and the overall lack of understanding of the precise mechanisms involved. The majority 
of the rodent models available strongly simulate specific pathologies of AD demonstrated 
in patients, such as plaques and tangles. There are numerous commonly used transgenic 
mouse models exploiting the human APP and PS1 genetic mutations implicated in early-
onset FAD (Holcomb et al., 1998; Hsiao et al., 1995; Neha et al., 2014; Yamada and 
Nabeshima, 2000). Furthermore, there are 3x transgenic mouse models that combine 
mutations in human APP, PS1 and tau genes and models integrating ApoE4 genetic 
mutations (Jucker, 2010; Medeiros et al., 2014; Oddo et al., 2003; Neha et al., 2014). 
These models often invariably develop amyloid plaques or NFTs, which are not always 
indicative of AD or represent a progressed disease state (Aizenstein et al., 2008; Dickson 
et al., 1992; Terry et al., 1987). Furthermore, the ApoE4 genetic background does not 
guarantee an eventual diagnosis of AD (Ringman et al., 2014; Selkoe 2001). Despite their 
shortcomings, all of these models have significantly advanced our understanding of the 
role of dysfunctional synaptic transmission and abnormal protein aggregation in AD. 
However, these models often fail to fully model the complex network of pathologies 
involved in the early stages of the disease. 
Transgenic rat models using the same genetic manipulations have recently been 
developed. Two rat models implement a mutant form of human APP (hAPP) with dual 
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Swedish and Indiana genetic mutations, which have been implicated in FAD. One model 
develops significant Aβ plaque accumulation, increased levels of neuroinflammation and 
ROS accompanied by cognitive deficits with age (Leon et al., 2010). The other model 
developed by Agca et al. (2008) produces increased levels of mutant hAPPSwe/Ind, but 
does not develop Aβ plaques with age. However, this model has been demonstrated to 
accumulate Aβ aggregates upon injection of human AD brain extracts (Rosen et al., 
2012). Additionally, kaolin-induced hydrocephaly increased oligomeric Aβ levels in the 
brain of this transgenic rat model (Silverberg et al., 2015). There are also rat models with 
genetic manipulations of both human APP and PS1 much like the mouse models (Cohen 
et al., 2013; Flood et al., 2009; Liu et al., 2008; Teng et al., 2011). The advancement into 
rat models is due to their closer relationship to humans genetically, morphologically and 
physiologically compared to mice (Do Carmo and Cuello, 2013; Jacob and Kwitek, 
2002), providing a strong rationale for the future use of rats to experimentally investigate 
the effects of Aβ in vivo. 
While the pathogenesis of AD in transgenic rodent models with FAD genetic 
backgrounds develops similar to sporadic AD and are commonly used in research 
approaches, other non-transgenic models of AD are available. These non-transgenic 
models can be used to investigate the behavioural and pathological impairments of AD. 
Through injection of Aβ25-35, a truncated form of Aβ42, into the intracerebral ventricles of 
the brain, a rat model was developed that exhibited a combination of AD pathologies 
(Amtul et al., 2014; Nell, 2013; Whitehead et al., 2005b; Whitehead et al., 2007). Aβ25-35 
is considered the core neurotoxic fragment of Aβ42 with better solubility, while 
maintaining the aggregation properties of Aβ42 (Kowall et al., 1992; Millucci et al., 2009; 
Pike et al., 1995; Yankner et al., 1989). Injection of this peptide into the brain has been 
shown to induce neuroinflammation, neurodegeneration, oxidative stress and cognitive 
deficits, creating a model with a complex neurotoxic pathological response to Aβ 
administration and demonstrating the early pathologies involved in the pathogenesis of 
AD (Amtul et al., 2014; Cheng et al., 2006; Kowall et al., 1992; Nell et al., 2014; 
Whitehead et al., 2005a, Whitehead et al., 2007; Zussy et al., 2013). All of these models 
have limitations in addition to their strengths, but still allow for a comprehensive 
approach to studying the complex nature of AD alone and in combination with other 
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diseases. These models can all be combined with stroke models to create co-morbid 
models, providing the ideal setting to elucidate the pathogenic impact of various 
mechanisms and direct future therapeutic approaches to battling AD in humans. 
1.11 Rationale 
There is an accumulation of clinical and experimental evidence demonstrating an 
interaction between stroke and AD, implicating stroke as both a risk factor for AD 
(Vermeer et al., 2007) and an exacerbating factor for pre-existing AD (Snowdon et al., 
1997). Both stroke and AD are becoming increasingly prevalent in the overall Canadian 
population, providing the impetus for a more comprehensive understanding of the 
synergism of these diseases and development of more effective therapeutic approaches. 
While there have been several studies exploring the co-morbid condition of stroke and 
AD, very few have utilized an animal stroke model relevant to the human condition. 
Several studies implement large MCAO infarcts or smaller infarcts localized to the 
hippocampus (Craig et al., 2009; Driscoll et al., 2008; McDonald et al., 2008). While 
these studies are valuable and sometimes relevant to a subset of human cases, clinical 
evidence has associated small striatal strokes in the pathogenesis of AD in humans 
(Snowdon et al., 1997; Vermeer et al., 2007). In order to simulate these clinically relevant 
strokes, localized striatal infarcts would be better suited for translational research.  
Several cellular factors have been identified in AD that are also implicated in 
stroke. Investigation of each disease independently has highlighted these commonalities 
and provided groundwork for the essential co-morbid studies required to better 
understand the synergism of stroke and AD. It has been well described that 
neuroinflammation plays a crucial role in the development stroke (Lakhan et al., 2009) 
and the early stages of cognitive decline in AD (Latta et al., 2014; Wyss-Coray and 
Mucke, 2002). Furthermore, oxidative stress is highly implicated in the development of 
stroke (Allen and Bayraktutan, 2009) and AD (Butterfield et al., 2001; Zhang et al., 
2015) and is a major consequence of normal aging, which is a major risk factor for 
developing AD. Oxidative stress is also largely associated with neuroinflammation and 
neurodegeneration. Treatment with non-steroidal anti-inflammatories often does not 
produce the desired outcome in regards to the improvement of cognitive function. 
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However, it is possible that treatment with these anti-inflammatories failed due to the 
timing of administration in regards to disease progression (Herrup, 2010) and their non-
specific, widespread mechanisms (Hensley, 2010). It has been previously demonstrated 
that treatment with the targeted antioxidant CAT-SKL is effective in the attenuation of 
Aβ-induced neuroinflammation, cholinergic loss and memory deficit in vivo (Nell, 2013). 
Furthermore, it has been effective in delaying the progression of cellular aging (Koepke 
et al., 2007) and attenuating ADDLs toxicity in vitro (Giordano et al., 2014).  
To further understand the complex pathophysiology of AD and stroke, this study 
focuses on the effect of striatal stroke in two different animal models of AD to better 
understand the role neuroinflammation has in cognitive decline in both instances. One 
model makes use of stroke as an exacerbating factor in combination with exogenous 
administration of Aβ, while stroke is used as an injury in the hAPPSwe/Ind transgenic rat 
for the second model. Moreover, this study is completed in six-month-old rats to better 
recapitulate the effect of age on the pathogenesis of both diseases (Nell et al., 2014). With 
age being the greatest risk factor for AD, this modification in age from the commonly 
used three-month animal model to a six-month model is highly beneficial, as it further 
parallels the aging factor of the clinical condition. To best assess the effects of the early 
pathological changes in the disease progression on the behavioural outcomes of the co-
morbid condition, a twenty-one day time point was chosen that results in microglial 
inflammation, neuronal death and cognitive deficits without the presence of amyloid 
plaques (Nell et al., 2014; Whitehead et al., 2007). The effectiveness of a targeted 
antioxidant therapeutic approach (CAT-SKL) is also investigated in the stroke and 
exogenous Aβ co-morbid model, with a focus on its influence on cognitive decline and 
microglial inflammation. 
1.12 Objectives and Hypotheses  
Objective 1: Determine the cellular pathologies and corresponding behavioural responses 
in a six-month-old rat model of co-morbid striatal stroke and intracerebroventricular 
injection of Aβ. 
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Hypothesis: The combination of stroke and Aβ toxicity in a rat model will 
exacerbate cognitive decline and neuroinflammation in comparison to stroke alone. 
Objective 2: Investigate the antioxidant and neuroprotective potential of CAT-SKL in 
rats subjected to co-morbid striatal stroke and intracerebroventricular injection of Aβ. 
Hypothesis: Treatment with CAT-SKL will decrease the behavioural and cellular 
pathological consequences of the combination of stroke and Aβ toxicity. 
Objective 3: Identify the behavioural responses and cellular pathologies of striatal stroke 
and Aβ toxicity in a mutant hAPPSwe/Ind transgenic rat model. 
Hypothesis: The combination of stroke and high levels of mutant hAPPSwe/Ind in a 
transgenic rat model will exacerbate cognitive decline and neuroinflammation 
compared to stroke in age-matched wild type rats. 
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Chapter 2: 
Methods
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2.1 Animal Husbandry 
All animal procedures were performed in accordance with the guidelines from the 
Canadian Council on Animal Care and were approved by the Western University Animal 
Use Subcommittee. Male wistar rats obtained from Charles River Laboratories (Montreal, 
QC) and in-house bred male Fisher 344 rats were aged to 6 months of age. Wistar rats 
were housed separately and Fisher 344 rats were housed in a colony prior to surgery. 
Post-surgery, Wistar rats were housed separately and Fisher 344 rats were housed 
separately for 24 hours and then housed in pairs for the remainder of the study. All rats 
were provided with food and water ad libitum and housed in standard conditions at 22-
24°C and on a 12 hr:12 hr light:dark cycle. Rats were randomly assigned to surgical and 
treatment groups prior to beginning the study. 
2.2 Transgenic Rat Model 
The transgenic rat model was developed on a Fisher 344 (F344) rat background 
using lentiviral gene therapy (Agca et al., 2008). The mutated hAPPSwe/Ind gene delivered 
contained both Swedish double missense (Swe) and Indiana single missense mutations 
(Ind), both of which have been associated clinically with familial AD and demonstrate 
AD pathology in animal models (Do Carmo and Cuello, 2013; Selkoe, 2001; Yamada and 
Yamada, 2000). The gene was under the ubiquitin-c promoter, which effectively 
delivered a single copy of the mutated hAPPSwe/Ind gene into the brain, kidney, lung and 
heart of F344 rats (Agca et al., 2008). This F344 transgenic rat model has been shown to 
endogenously express high levels of mutant hAPPSwe/Ind, in addition to endogenous 
production of APP, but do not develop amyloid plaques with age. However, significant 
Aβ accumulation is present after external intervention, such as injection of AD patient 
brain extract into the hippocampus (Rosen et al., 2012) or kaolin-induced hydrocephaly 
(Silverberg et al., 2015). Both F344 wild type and F344 transgenic rats were obtained 
directly from the Agca laboratory (Colombia, MO) and homozygous bred in our animal 
facility. PCR gene analysis was completed to ensure only F344 wild type rats and F344 
rats homozygous for the hAPPSwe/Ind gene were included in this study.  
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2.3 ET-1 and Aβ Preparation 
ET-1 is a protein that acts as a vasoconstrictor in the cardiovascular system 
(Yanagisawa et al., 1988). Using a targeted injection of human ET-1 induces transient 
focal ischemia approximately 1 hour in duration in rodents and can be used to effectively 
model the small striatal strokes observed in human AD patients (Amtul et al., 2014; 
Whitehead et al., 2005a). Human ET-1 (Sigma-Aldrich Canada Co., Oakville, ON) was 
dissolved in sterile saline achieving a final concentration of 60 pmol. ET-1 was then 
aliquoted into eppendorf tubes at a 10 µL volume and stored at –80°C until required for 
use. Sterile saline was used as a control for the ET-1 injections.  
The neurotoxic core of the Aβ42 peptide, Aβ25-35 (Bachem Americas Inc., 
Torrence, CA), was dissolved in sterile saline creating a 500 nmol concentration and 
aliquoted into eppendorf tubes. 30 µL aliquots were stored at –80°C until required for use. 
The non-toxic reverse peptide Aβ35-25 (Bachem Americas Inc., Torrence CA) was 
dissolved in sterile saline achieving a 500 nmol concentration providing the control for 
surgical procedures. Aβ35-25 was aliquoted and stored in the same manner as the Aβ25-35. 
The shorter, neurotoxic Aβ25-35 conserves the biological properties of the canonical full-
length Aβ42 peptide, while allowing for better diffusion (Kowall et al., 1992; Millucci et 
al., 2009; Pike et al., 1995; Yankner et al., 1989). The use of Aβ25-35 to model AD-like 
pathophysiology has been verified in numerous rodent models (Amtul et al., 2014; Cheng 
et al., 2006; Kowall et al., 1992; Nell et al., 2014; Whitehead et al., 2005a, Whitehead et 
al., 2007; Zussy et al., 2013).  
2.4 Surgical Procedures 
All rats were anesthetised with 3% isofluorane (Baxter Corporation, Mississauga, 
ON) at 2% of total airflow on 2 L/min oxygen supply in a Harvard anaesthesia box 
(Harvard Apparatus, Holliston, MA) attached to a tabletop anethesia machine (VetEquip 
Inc., Livermore, CA). Once anesthetised, the head of the rat was shaved and rats were 
secured in a David Kopf stereotaxic surgical apparatus (David Kopf Instruments, 
Tujunga, CA) using ear and incisor bars. The temperature of the rats was maintained at 
37°C using a heating pad throughout the surgical procedure. Rats remained anesthetised 
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on gas anesthesia for the duration of the surgery through a nosepiece. The anesthesia was 
decreased to 1.75% of total airflow after skin incision was complete. Soap, ethanol and 
iodine were used to sterilize the exposed skin at the surgery site. The skull was then 
exposed and the landmarks Lambda and Bregma were located. The ear and incisor bars 
were adjusted accordingly to ensure that these landmarks were aligned at the same height. 
Bregma was located and marked and its coordinates were used to identify the brain 
regions for injection. Once all brain regions were located and marked, small burr holes in 
the skull were made for insertion of an injection syringe.  
All surgical reagents (ET-1, Aβ) were kept on dry ice prior to injection during 
surgery. AD was modeled through bilateral intracerebroventricular injections of 25 µL of 
500 nmol Aβ25-35 using a 25 µL Hamilton® syringe (Hamilton Company, Reno, NV). 
Coordinates of the ventricles with respect to Bregma were ±1.4 mm medial-lateral (ML), 
-0.8 mm anterior-posterior (AP) and -4.0 mm dorsal-ventral (DV). Injections were 
completed over twenty minutes per ventricle (1.78 µL/min) with two in situ periods of 3 
minutes. Control surgical procedures were completed with Aβ35-25 using the same 
injection paradigm.  
To induce transient focal ischemia, small lacunar strokes were induced through 
unilateral right striatal injection of 3 µL of 60pmol ET-1 using a 5 µL Hamilton® syringe 
(Hamilton Company, Reno, NV). Coordinates of the striatum with respect to Bregma 
were -3.0 mm ML, +0.5 mm AP and -5.0 mm DV. Injections were completed over 5 
minutes (0.6 µL/min) with an in situ period of 3 minutes following the injection. Sterile 
saline was injected in the same manner as a control. 
Following completion of injections, rats were administered the analgesic 
buprenorphrine (0.03 mg/mL, Champion Alstoe Animal Health, Whitby, ON) at a dose of 
1 mg/kg subcutaneously. Additionally, rats were administered 0.03 mL of the antibiotic 
Baytril® (22.7 mg/mL enrofloxacin, Bayer HealthCare Animal Health, Mississauga, 
ON). The surgery site was sutured closed and rats remained in the surgical apparatus with 
pure oxygen at 2 L/min for 1 minute. Following oxygen administration, rats were closely 
monitored under a heat lamp during recovery until they regained sternal recumbency. 
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2.5 CAT-SKL Administration  
CAT-SKL is an engineered enzyme different from the canonical catalase due to its 
altered protein-targeting signal. The sequence of the core catalase enzyme is conserved in 
the recombinant protein, but CAT-SKL has a serine-lysine-leucine (SKL) targeting 
sequence. Furthermore, the enzyme has a cell penetrating peptide attached to assist with 
cellular and tissue delivery (Giordano and Terlecky, 2012; Koepke et al., 2007). CAT-
SKL was obtained from Dr. Paul Walton and Dr. Stanley Terlecky (United States patent 
7601366 and related patents pending) and stored at 4°C. Rats were randomly assigned to 
either CAT-SKL or vehicle treatment groups. Stock CAT-SKL (9 mg/mL) was diluted in 
sterile saline to 1 mg/mL. Wistar rats were administered 1 mg/kg of CAT-SKL or the 
equivalent volume of saline intraperitoneally. Treatment was administered weekly for 
four weeks starting one week prior to their scheduled surgery date.  
2.6 Surgical Groups 
The stroke model procedure was implemented the same in both the Wistar and 
hAPPSwe/Ind transgenic and wild type Fisher 344 rats to model small lacunar stokes in the 
striatum. The Aβ surgical intervention was only completed in the Wistar rats to model 
AD. The Aβ paradigm was combined with the stroke procedure to model a co-morbid 
stroke/Aβ rat. Control rats underwent the same surgical procedures with the injection 
combination of saline and reverse peptide Aβ35-25 (RP). Table 1 and Table 2 provide a 
summary of surgical interventions along with the corresponding animal numbers for each 
animal model. 
2.7 Behaviour: Cylinder Task 
 The cylinder task assesses the use of forelimbs when contacting the wall of the 
cylinder apparatus during spontaneous rearing. This task is commonly used to measure 
forelimb gross motor function and symmetry between forelimbs (Schallert et al., 2002). 
The cylinder task testing was completed on day -3, 3, 7 and 20 for Wistar rats and on day 
-3, 7 and 20 for hAPPSwe,/Ind transgenic rats in regards to surgery day (day 0). Rats were 
placed in a plexiglass cylinder apparatus (23 cm diameter x 40 cm height) with a 
perforated lid. A mirror was placed at a 45° angle below the cylinder and a video camera 
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was positioned to record the full width of the cylinder from the mirror. Each trial had a 
duration of 5 min and three trials were recorded for each testing day. A ring of coloured 
tape was placed along the wall three-quarters from the bottom of the cylinder and banana 
and almond extract (Goodas Food Products Co. LTD., Concord, ON) were applied to the 
tape to motivate spontaneous rearing during testing.  
All videos were compiled and rendered using iMovie for quantitative analysis. 
Two individuals, blinded to the rat’s surgical identity, analyzed the use of the rat’s 
forelimbs during each trial using the compiled videos. The percent of affected forelimb 
use was calculated with the following equation: [{(affected contacts + ½ bilateral 
contacts)/total number contacts}x100]. Each individual rat’s post-surgery values were 
then standardized to their pre-surgery values as follows: [(post-surgery percent of affected 
forelimb use/pre-surgery percent of affected forelimb use)]. The criterion for each trial 
was set at six or more forelimb contacts and trials where animals failed to meet six 
forelimb contacts were excluded. If an animal did not meet the criterion in all three trials, 
the animal was excluded entirely.  
2.8 Behaviour: Modified Sticky Tape Task 
Sughrue et al. (2006) adapted the modified sticky tape (MST) task from the 
conventional sticky tape task. Assessment of fine motor function and somatosensory 
function in the forelimbs was measured through MST analysis. Wistar rats completed the 
MST on day -1, 3 and 21 in regards to surgery day (day 0). A small piece of tape was 
wrapped around the rat’s forelimb and the rat was placed into a clean cage for 45 sec. 
Two individuals, blinded to the rat’s surgical identity, analyzed the amount of time the rat 
spent attending to the tape during the trial. Three trials for each forelimb were completed 
on each testing day giving a total of 6 trials per testing day.  
The ratio of the time spent attending to the affected forelimb in comparison to the 
unaffected forelimb was calculated and post-surgery values were standardized to pre-
surgery values using the following equation: [(post-surgery ratio of affected forelimb 
use/pre-surgery ratio of affected forelimb use)]. If an animal completely neglected to 
attend to the tape on either forelimb on any testing day, the animal was excluded entirely. 
  27 
Table 1. Stroke and Aβ injection rat model summary of surgical procedures and 
treatment groups with corresponding animal numbers. Only animals that underwent 
successful surgeries and were included in behavioural and immunohistochemical analysis 
are listed. Abbreviations are as follows: RP = reverse peptide Aβ35-25, Aβ = neurotoxic 
Aβ25-35 and CAT-SKL = catalase with serine-lysine-leucine targeting sequence. 
Striatal Injection 
Bilateral 
Ventricular 
Injection 
Treatment Number of Animals 
Saline RP Saline 6 
Stroke (ET-1) None Saline 7 
Stroke (ET-1) None CAT-SKL 8 
Stroke (ET-1) Aβ Saline 8 
Stroke (ET-1) Aβ CAT-SKL 8 
 
 
Table 2. Summary of surgical procedures with corresponding animal numbers for 
the hAPPSwe/Ind transgenic rat model. The number of animals with successful surgeries 
included in behavioural and immunohistochemical analysis and are listed. Abbreviations 
are as follows: WT = wild type animal and TG = transgenic animal. 
Genetic Background Surgical Procedure Number of Animals 
WT Saline 8 
WT Stroke 9 
TG Saline 8 
TG Stroke 8 
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2.9 Behaviour: Beam-walk Task 
The beam-walk task was implemented to measure motor function in the hindlimbs 
when completing a skilled movement requiring accurate foot placement and balance. 
hAPPSwe/Ind transgenic and wild type rats were trained to walk across a 1.9 cm wide 
wooden beam secured approximately 40 cm above the ground. The environment 
enrichment tubing from the rat’s home cage was placed at the opposite side of the beam 
as motivation to walk across the beam. During training, rats were guided to walk across 
the beam. Once rats crossed the beam without assistance, the training session was ceased. 
A video camera was positioned to view the full length of the beam and six trials (three in 
each direction) were recorded on day -7 and day 21 with respect to surgery day. All 
videos were compiled and rendered using iMovie for quantitative analysis. Two 
individuals, blinded to the rat’s surgical identity, quantified the number of hindlimb errors 
and total steps required to cross the beam using the compiled videos. Hindlimb errors 
were standardized to the number of total steps and the difference between pre-surgery and 
post-surgery errors was calculated (post-surgery errors – pre-surgery errors). 
2.10 Behaviour: Morris Water Maze 
Morris water maze (MWM) testing is a commonly used paradigm for assessment 
of learning and memory, specifically focusing on spatial learning and memory (Vorhees 
and Williams, 2006). The MWM consisted of a circular pool (148 cm diameter x 58 cm 
depth) filled with 36 cm deep water. The water was made opaque using non-toxic black 
paint and the temperature was kept at approximately 21°C. The pool was divided into 
four equal quadrants designated as northeast (NE), southeast (SE), southwest (SW) and 
northwest (NW). A room divider was placed on one side of the pool to create an enclosed 
pool area that allowed experimenters to be out of sight during testing. All trials were 
recorded through a webcam (Logitech, Newark, CA) positioned above the center of the 
pool and connected to a laptop. Behavioural data (i.e. swimming speed, distance and 
latency) was compiled in ANY-maze® video-tracking software (Stoelting CO, Wood 
Dale, IL). Outside the NW quadrant, a radio at low volume was on during all testing to 
provide background noise. This was used to avoid sudden startle responses to unexpected 
  29 
loud noises during testing. Wistar and Fisher hAPPSwe/Ind transgenic and wild type rats 
completed three phases of testing: spatial learning, probe testing and cued learning. 
Furthermore, two additional groups (Aβ + saline and Aβ + CAT-SKL) from a previous 
investigation for which the original MWM data was available were analyzed in the 
manner in this study and included with the MWM data for the stroke/Aβ injection model.  
During spatial learning, rats were trained to locate a hidden stationary platform in 
the SW quadrant. External cues were placed along the walls and the divider to assist rats 
in locating the platform. 4 trials per day were completed over 4 days of training for a total 
of 16 trials starting on day 8 after surgery (day 0). An inter-trial interval time of 20 min 
was allotted for each rat. Rats were placed in the pool at one of the four designated start 
positions (N, E, SE, NW) assigned randomly prior to testing and given 90 sec to find the 
location of the platform. If a rat did not find the platform, they were guided to its location. 
If a rat was successful in finding the platform, the tracking software was stopped and the 
trial ended. During the first two days of training, rats were required to remain on the 
platform for 30 sec upon finding the platform. A rat was not removed from the water until 
they had remained on the platform for 30 sec consecutively. After two days of training, 
rats were only required to sit on the platform for 15 sec. Distance and latency to reach the 
platform were measured as an indication of learning. 
Following completion of spatial learning, a single probe trial was conducted on 
days 12 and 19 to assess short-term and long-term spatial reference memory, respectively. 
The platform was removed from the pool and the extra-maze cues remained in place. 
Each rat was released into the pool from the NE start position and allowed to swim for 30 
sec. Once the probe trial was completed on day 12, the platform was returned to the SW 
quadrant of the pool while the rat remained in the pool. A rat was required to remain on 
the platform for 10 seconds before they were retrieved from the pool in order to avoid 
memory extinction on day 19. Spatial reference memory was measured as the latency to 
first enter the SW quadrant target zone. If atatistically significant differences in speed 
during probe testing was observed, this was corrected for using the following equation: 
({[rat swim speed/average group swim speed] x latency to first enter the target zone}). 
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As a control, cued learning trials occurred after all probe trials were completed on 
day 20 and 21. Cued learning assessed any potential differences in motivation to escape 
the MWM and the ability to use spatial cues to locate a hidden platform. During cued 
learning, a cue was attached to the platform that was visible above the water and all extra-
maze cues were removed. The platform (NE, SE, SW, NW) and start (N, E, S, W) 
position combination was varied every trial for each rat. A rat was released into the pool 
at a designated start position and was allotted 60 sec to locate the platform. Upon 
reaching the platform on day 20, rats were required to remain on the platform for 15 sec 
before they were retrieved from the pool. On day 21, rats were removed from the pool 
immediately upon finding the platform. Quantifying the distance and latency to reach the 
platform assessed cued learning.  
2.11 Behaviour: Summary of Timelines 
Each model was subjected to a different behavioural paradigm and timeline. The 
stroke and Aβ injection model completed the cylinder task, MST task and MWM and a 
summary of the experimental protocol in regards to surgery day (day 0) is provided in 
Figure 1. The hAPPSwe/Ind transgenic model completed the cylinder task, beam-walk task 
and MWM and the timeline is summarized in Figure 2. 
2.12 Euthanasia 
Twenty-one days post-surgery, rats were be administered a 2.0 mL overdose of 
euthanyl (240 mg/mL, Bimeda-MTC Animal Health Inc., Cambridge, ON) 
intraperitoneally. Following drug administration, rats were transaortically perfused with 
0.01 M phosphate-buffered saline solution (PBS, pH 7.35) for 3 min. Subsequently, rats 
were formalin-fixed with 4% paraformaldehyde (PFA) for 7 min. Perfused brain tissue 
was extracted and placed in a vial for further fixation with 4% PFA for 24 hr at 4°C and 
then was transferred into 30% sucrose and stored at 4°C until sectioning. 
2.13 Immunohistochemistry: Microglia 
 Formalin-fixed brain tissue was sliced into 35 µm coronal sections using the 
Cryostar NX50 Cryostat (Thermo Fisher Scientific Inc., Waltham, MA) and free-floating 
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Figure 1. Stroke and Aβ injection model behaviour timeline. All testing days are in 
reference to surgery day 0. (A) Pre-surgery testing for the cylinder task (C) and 
modified sticky tape task (MST) was completed on day -3 and -1, respectively. Post-
surgery testing for C occurred on day 3, 7 and 20 and MST testing occurred on day 3 
and 21. (B) MWM spatial learning was completed day 8, 9, 10 and 11 with probe trials 
following on day 12 and 19. Cued learning occurred on day 20 and 21.
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Figure 2. hAPPSwe/Ind transgenic rat model behavioural paradigm for motor and 
cognitive tasks. Surgery day is assigned day 0 and all testing days are in reference to 
this day. (A) Pre-surgery testing for cylinder task (C) and beam traversing task (BM) 
was completed on day -3 and -7, respectively. Post-surgery testing occurred on day 7 
and 20 for C and day 21 for BM. (B) Morris Water Maze spatial learning was 
completed day 8, 9, 10 and 11 with probe trials following on day 12 and 19. Cued 
learning occurred on day 20 and 21.
  33 
sections were divided into a series of 6 and stored in cryoprotectant (sucrose, ethylene 
glycol, phosphate buffer) at –20°C until required for immunohistochemical processing. 
Formalin-fixed brain slices were analyzed for microglial activation with a two-day 
immunohistochemistry protocol. A single series of a 6 series division was further divided 
into a series of 3 and 2 series of the 3 were immunohistochemically processed. On day 1, 
brain sections were washed with 0.1 M PBS (pH 7.35) six times for 10 min to remove 
residual cryoprotectant. To block endogenous peroxidase activity in the brain tissue, 
sections were then incubated in 1% H2O2 for 10 min. Sections were then washed with 0.1 
M PBS (pH 7.35) three times for 5 min before being incubated in 2% horse serum 
blocking solution consisting of horse serum (HO146, Sigma Aldrich Canada Co., 
Oakville, ON) diluted in 0.2% PBST (0.1 M PBS, pH 7.35 with 0.2% Triton X-100) for 1 
hr. Sections were then incubated on a shaker at 4°C overnight with a 1:1000 dilution of 
the OX-6 primary antibody (RT1B purified monoclonal mouse, BD Pharmingen™, 
Mississauga, ON) with 2% horse serum blocking solution. The OX-6 primary antibody 
detects MHC-II receptors on activated microglial cells. 
On day 2, sections were washed with 0.1 M PBS (pH 7.35) three times for 5 min. 
Following washing, sections were incubated with biotinylated horse anti-mouse IgG (H + 
L) secondary antibody (Vector Laboratories Canada Inc., Burlington, ON) diluted to 
1:500 with 2% horse serum blocking solution for 1 hr. Sections were subsequently 
washed with 0.1 M PBS (pH 7.35) three times for 5 min. Sections were then incubated in 
Avidin-Biotin Complex reagent (Vector Laboratories Canada Inc., Burlington, ON) 
prepared in 0.2% PBST for 1 hr. Again, sections were washed with 0.1 M PBS (pH 7.35) 
three times for 5 min. Sections were then incubated in 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma Aldrich Canada Co., Oakville, ON) diluted to 0.05% in 0.1 M 
PBS (pH 7.35) with 1% H2O2 for 2 – 3 min. Sections were washed in 0.1 M PBS (pH 
7.35) three times for 5 min and mounted on VWR VistaVision™ microscope slides 
(VWR International LLC., Mississauga, ON) with 0.3% gelatin and left to air dry 
overnight. After drying, the slides were dehydrated through a series of increasing ethanol 
concentrations (50%, 70%, 95%, 100%) for 5 minutes at each concentration. Slides were 
then immersed in a 50% ethanol/50% xylene solution for 5 minutes and subsequently 
immersed in 100% xylene for 10 minutes. The slides were covered with microscope slide 
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coverslips using DEPEX mounting media (Electron Microscopy Sciences, Hatfield, PA, 
USA) immediately after immersion in xylene.  
2.14 Imaging 
Immunohistochemically processed brain sections were imaged with a Nikon 
Eclipse Ni-E microscope using NIS-Elements Imaging Software Version 4.30.02 (Nikon 
Instruments Inc., Melville, NY). Regions of interest for analysis included the infarct area 
in the striatum (between Bregma 2.28 mm and -1.44 mm) and the basal forebrain 
(Bregma 0.96 – 0.36 mm). Images for analysis of the striatum and the basal forebrain 
were taken at 2x and 10x magnification, respectively.  
2.15 Immunohistochemical Quantification 
OX-6 microglial inflammation analysis was completed using the 64-bit ImageJ 
software (Version 1.48u4, Wayne Rasband, National Institutes of Health, Bethesda, MD). 
Two individuals, blinded to the surgical identity of the rats, completed all 
immunohistochemical analysis. OX-6 inflammation volume in the striatum was 
calculated using the following equation: [(ΣOX-6 imuunolabelled surface area) x ({n-
1}{0.035}{0.315})], where n = number of immunolabelled sections, 0.035 mm is the 
thickness of the sections and 0.315 mm is the distance between adjacent sections. OX-6 
microglial cell counts were completed on a total of four consecutive sections 
corresponding to the basal forerbrain (Bregma 0.96 – 0.36 mm). Counts were completed 
by manually selecting positively immunostained microglia in the predefined basal 
forebrain region.  
2.16 Statistical Analysis 
One-way and two-way analysis of variance (ANOVA) was completed with a 
Tukey’s or Bonferroni multiple comparisons post hoc test using GraphPad Version 6.0 
software for Mac (GraphPad Software Inc., La Jolla, CA). Data is represented as the 
mean ± SEM with corresponding analysis methods noted in the figure legends. A value of 
p ≤ 0.05 was considered significant and where necessary asterisks denote significance on 
data sets.
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Chapter 3: 
Results
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3.1 Stroke and Aβ Injection Model: Effect of Antioxidant CAT-SKL 
3.1.1 Motor Function in the Cylinder Task 
Stroke is often associated with phenotypic motor deficits that result due to the loss 
of brain function within the infarct area. Previous studies that have demonstrated 
exacerbated motor deficits in the co-morbid AD/stroke condition lead to the use of the 
cylinder task to investigate motor function in this model (Biernaskie and Corbett, 2001; 
Clarke et al., 2007; Soleman et al., 2010). The goal of the cylinder task was to assess the 
effect of stroke and the co-morbid condition on forelimb motor function and symmetry. 
Due to the connectivity of the brain, stroke that is constrained to one hemisphere results 
in one-sided motor deficits affecting the side of the body contralateral to the stroke. In the 
animal models used, the stroke is induced in the right striatum and motor deficits should 
occur in the left side of the body. Therefore, the left is considered the affected side.  
The percent of affected forelimb use was standardized to individual baseline (day 
-3) values resulting in an affected forelimb use score. A score of 1.0 represents the equal 
use of the unaffected and affected forelimb when contacting the wall of the cylinder 
during spontaneous rearing. Scoring greater than 1.0 represents a greater use of the 
affected forelimb and scoring less than 1.0 signifies a greater use of the unaffected 
forelimb. In the cylinder task, there were no significant differences in affected forelimb 
use between testing days in any surgical group (Figure 3).  
3.1.2 Motor Function in the Modified Sticky Tape  
Other levels of motor function can also be affected by stroke and the co-morbid 
condition. MST task testing was aimed at assessing fine motor function and 
somatosensory function in the forelimb. Quantification of the time spent attending to the 
tape on each forelimb was recorded and a ratio of time attending to affected compared to 
unaffected forelimb was calculated. Subsequently, ratios were standardized to baseline 
(day -1) values resulting in a standardized ratio score. A ratio greater than 1.0 signifies 
greater attendance to the affected forelimb and less than 1.0 represents greater attendance 
to the unaffected forelimb. A score equal to 1.0 represents equal attending time to the 
affected and unaffected forelimb. For all surgical groups, no significant differences
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Figure 3. Testing forelimb gross motor function using the cylinder task. Percent use 
of affected forelimb was calculated ({[affected contacts + 1⁄2 bilateral contacts]/total 
number contacts}x100) and averaged over 3 trials per day. The average percent of 
contralateral forelimb use was then normalized to individual day -3 pre-surgery values 
(post-surgery % affected forelimb use/pre-surgery % affected forelimb use). The red 
dotted line at the level of 1.0 on the y-axis represents the equal use of the affected and 
unaffected forelimb during spontaneous rearing. Animal numbers are as follows: 
saline/RP + saline (n=6), stroke + saline (n=5), stroke + CAT-SKL (n=8), stroke/Aβ + 
saline (n=8), stroke/Aβ + CAT-SKL (n=8). Values are presented as mean ± SEM. (Two-
way ANOVA, Tukey post hoc test). 
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Figure 4. Fine motor or somatosensory function assessment using the modified 
sticky tape task. The ratio of the time spent attending to the tape on the affected forelimb 
compared to the unaffected forelimb was calculated and averaged over 3 trials per day. 
Average ratios were then normalized to individual day -3 pre-surgery values (post-
surgery time attending to affected forelimb/pre-surgery time attending to affected 
forelimb). The red dotted line at the level of 1.0 on the y-axis represents the equal use of 
the affected and unaffected forelimb. Animal numbers are as follows: saline/RP + saline 
(n=6), stroke + saline (n=6), stroke + CAT-SKL (n=8), stroke/Aβ + saline (n=7), 
stroke/Aβ + CAT-SKL (n=8). Values are presented as mean ± SEM. (Two-way ANOVA, 
Tukey post hoc test).  
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were observed in time spent attending to the affected forelimb between testing days 
(Figure 4). 
3.1.3 Attenuation of Cognitive Deficit in Co-morbid Condition with 
CAT-SKL 
Spatial learning and reference memory in the MWM was a test of cognitive 
processes often mediated by the hippocampus, a highly vulnerable area of the brain in 
AD (D’Hooge and De Deyn, 2001; Gouras et al., 2000; Selkoe, 2001). While clinically it 
has been demonstrated that patients with stroke and AD present with worse cognitive 
deficits than those with AD alone (Schneider et al., 2007; Snowdon et al., 1997), there 
has been a lack of experimental evidence investigating this interaction. All learning and 
memory testing was completed after induction of stroke and Aβ toxicity to assess the 
effect of the co-morbid condition on learning and memory. Moreover, this testing 
allowed assessment of the effectiveness of CAT-SKL in attenuating cognitive deficits.  
Latency and distance to reach the platform were measured as indicators of 
learning. Latency to reach the platform decreased significantly over 4 days of spatial 
learning for all surgical groups (day 8 vs. day 11, p < 0.05, Figure 5A). This effect was 
also observed in the distance to reach the platform, which significantly decreased over the 
course of learning for all surgical groups (day 8 vs. day 11, p < 0.05, Figure 5B). The 
decreased latency and distance to reach the platform signified that all groups successfully 
learned to locate the platform and the extent of learning was the same between all groups, 
as there were no differences between surgical groups on any testing day (Figure 5A-B). 
Swim speed was also monitored during learning to ensure there were no differences 
between groups that would account for the decreased latency and distance to reach the 
platform. There were no significant differences in swim speed across all surgical groups 
observed on any of the testing days (Figure 5C).  
Spatial reference memory was measured as the latency to first entry into the target 
zone during a probe trial where the platform is removed. The target zone is the quadrant 
where the platform was located during spatial learning. Memory was tested 24 hours after 
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Figure 5. Spatial learning of hidden platform location in MWM. Spatial learning is 
represented as latency (A) and path length (B) to reach the platform across four 
consecutive days of learning. Swim speed (C) was monitored during spatial learning to 
ensure differences in latency and path length were not due to speed differences. Animal 
numbers are as follows: saline/RP + saline (n=4), Aβ + saline (n=9), Aβ+ CAT-SKL 
(n=8), stroke + saline (n=7), stroke + CAT-SKL (n=8), stroke/Aβ + saline (n=8), 
stroke/Aβ + CAT-SKL (n=8). All values are presented as mean ± SEM. (Two-way 
ANOVA, Tukey post hoc). 
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spatial learning (day 12) and one week following spatial learning (day 19) to test short-
term and long-term memory, respectively. The co-morbid group treated with saline 
(stroke/Aβ + saline) required a significantly greater latency to first enter the target zone 
on day 19 compared to day 12 (p < 0.05, Figure 6). This effect was not demonstrated in 
the control groups, Aβ or stroke alone groups (Figure 6). Furthermore, there was no 
difference in latency to first entry into the target zone observed in the co-morbid group 
treated with CAT-SKL (stroke/Aβ + CAT-SKL, Figure 6), indicating that CAT-SKL 
attenuated the memory deficits observed in the co-morbid condition. To account for 
differences in latency due to swim speed, the swim speed was also measured during 
memory testing. There were no differences in swim speed between surgical groups or 
days during probe testing (data not shown). Furthermore, percent time in the target zone 
during probe testing was analyzed, but was not significant between groups (data not 
shown). 
 Cued learning was completed to ensure there were no differences in the ability to 
use visual cues for orientation and motivation to escape the pool. Learning was measured 
as the latency and distance to reach the platform and swim speed was monitored. All 
measurements were averaged over two days of learning. There were no significant 
differences in latency and distance to reach the platform or swim speed across all surgical 
groups (Figure 7A-C). This suggests that all groups were able to use spatial cues to locate 
the platform and were equally motivated to escape the pool. 
3.1.4 Microglia Within the Infarct Area 
Neuroinflammation has a major role in the pathophysiology of AD and stroke with 
emphasis on the role of microglia in the development of both diseases (Heneka et al., 
2015; Latta et al., 2014; Lee et al., 2010; Tuppo and Arias, 2005). The extent of microglia 
within the infarct region was measured as an area of activated microglia. The antibody 
OX-6 labels microglia presenting the MHC-II complex, which signifies an activated 
phagocytic state (Akiyama et al., 2000; Luber-Narod and Rogers, 1988, Wang et al., 
2007). Across all groups there were no significant differences in the volume of 
inflammation in the right striatum (Figure 8F).  
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Figure 6. CAT-SKL rescues reference memory deficits in co-morbid animals in 
MWM. Spatial reference memory is represented as the latency to first enter the target 
zone during probe testing on day 12 and 19. The target zone is the quadrant that housed 
the hidden platform during spatial learning. Animal numbers are as follows: saline/RP + 
saline (n=4), Aβ + saline (n=9), Aβ + CAT-SKL (n=8), stroke + saline (n=7), stroke + 
CAT-SKL (n=8), stroke/Aβ + saline (n=8), stroke/Aβ + CAT-SKL (n=8). All values are 
presented as mean ± SEM and significance is represented with an asterisk. (p < 0.05, 
Two- way ANOVA, Bonferroni post hoc).  
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Figure 7. Cued learning of a hidden platform with a visible cue attached in the 
MWM. Latency (A) and path length (B) to reach the platform are represented as an 
average of all eight trials across two days of cued learning. Swim speed (C) is presented 
as an average of all eight trials across two days of cued learning. Animal numbers are as 
follows: saline/RP + saline (n=4), Aβ + saline (n=9), Aβ + CAT-SKL (n=8), stroke + 
saline (n=7), stroke + CAT-SKL (n=8), stroke/Aβ + saline (n=8), stroke/Aβ + CAT-SKL 
(n=8). Values are presented as the mean ± SEM. (One-way ANOVA, Tukey post hoc).
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Figure 8. Microglial expression within the right striatum infarct area. (A-E) 2X 
photomicrographs of representative microglial inflammation in the right striatum. (F) 
Volume of the right striatal inflammation based on the extent of OX-6 immunolabelled 
microglia. Volume was calculated using the following equation: [(ΣOX-6 
immunolabelled surface area) x ({n-1}{0.035}{0.315})] where n = number of OX-6 
immunolabelled sections. Scale bar = 1 mm. Animal numbers are as follows: saline/RP + 
saline (n=6), stroke + saline (n=7), stroke + CAT-SKL (n=8), stroke/Aβ + saline (n=8), 
stroke/Aβ + CAT-SKL (n=8). Values are presented as the mean ± SEM. (One-way 
ANOVA, Tukey post hoc).
  45 
3.1.5 CAT-SKL Attenuates Microglial Expression Within the Basal 
Forebrain 
The basal forebrain is one of the earliest brain structures affected in the 
pathogenesis of AD (Auld et al., 2002; Stepanichev et al., 2004; Vaucher et al., 2001). 
Coupled with evidence of neuroinflammation present in the early stages of AD and its 
connectivity to the hippocampus, the basal forebrain is a major region of interest in 
regards to the early stages of AD. The co-morbid group treated with saline (stroke/Aβ + 
saline) demonstrated greater microglial numbers in the basal forebrain compared to both 
stroke alone groups (p < 0.05, Figure 9L). In comparison to the control group, the co-
morbid group treated with saline was the only group with significantly increased 
microglia in the basal forebrain (p < 0.05, Figure 9L). The lack of significance between 
the co-morbid group treated with CAT-SKL and the control and stroke alone groups 
suggests that CAT-SKL was able to attenuate the level of microglia in the basal forebrain 
in the co-morbid condition.
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Figure 9. CAT-SKL attenuates microglial numbers within the basal forebrain of co-
morbid animals. Representative 2X (A-E) and 10X (F-J) photomicrographs of 
microglia in the basal forebrain. Boxed areas in A-E represent the area in the 10X 
photomicrographs that accurately represented the mean microglial cell count for each 
group. (K) Atlas representation of rat brain with sections used in counting outlined with 
thick black lines. (L) Microglial cell counts of 10X photomicrographs of OX-6 
immunolabelled basal forebrain sections. Scale bar in E = 1mm. Scale bar in J = 100 µm. 
Animal numbers are as follows: saline/RP + saline (n=6), stroke + saline (n=6), stroke + 
CAT-SKL (n=8), stroke/Aβ + saline (n=6), stroke/Aβ + CAT-SKL (n=7). Values are 
presented as mean ± SEM and significance is represented with an asterisk. (p < 0.05, 
One-way ANOVA, Tukey post hoc).
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3.2 Stroke and hAPPSwe/Ind Transgenic Rat Model: Effect of Stroke 
Injury  
3.2.1 Motor Function in the Cylinder Task 
Previous studies have demonstrated an exacerbation in stroke behavioural 
pathology in the co-morbid AD and stroke condition (Biernaskie and Corbett, 2001; 
Clarke et al., 2007; Soleman et al., 2010; Whitehead et al., 2005a; Whitehead et al., 
2007). The cylinder task measures gross motor function in the forelimbs during 
spontaneous rearing and affected forelimb use was standardized to baseline values (day -
3). Statistical analysis did not show significant differences in affected forelimb use 
between days across all surgical groups (Figure 10).  
3.2.2 Motor Function in the Beam Walk Task 
There is a great deal of evidence implicating subtle changes in gait and balance in 
AD patients in the early stages of the disease (Sheridan and Hausdorff, 2007), but the 
effect of the interaction between stroke and AD on gait has rarely been investigated. The 
task of walking across a thin wooden beam requires a greater level of coordination and 
skilled limb control compared to the motor function required in the cylinder task. 
Hindlimb function was measured as the number of errors per step across the entire length 
of the beam for the affected and unaffected hindlimbs. These values were standardized to 
baseline (day -7) errors per step resulting in a hindlimb error score. Furthermore, total 
steps were presented as the raw number of steps required to cross the full length of the 
beam. The number of errors was relatively low (less than or equal to 1 error in total) 
across all six trials and there were no significant differences observed for the hindlimb 
error score for the affected or unaffected hindlimb between groups (Figure 11A-B). 
However, the co-morbid condition (transgenic + stroke) was the only group that required 
significantly more steps to cross the beam on day 21 compared to day -7 (p < 0.05, Figure 
11C). This may indicate early changes in the gait pattern of the transgenic + stroke group 
as a result of the co-morbid condition.  
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Figure 10. Assessment of gross forelimb motor function using the cylinder task. 
Percent use of affected forelimb was calculated ({[affected contacts + 1⁄2 bilateral 
contacts]/total number contacts}x100) and averaged over 3 trials per day. Averaged 
values were then normalized to individual day -3 pre-surgery values (post- surgery % 
affected forelimb use/pre-surgery % affected forelimb use). The red dotted line at the 
level of 1.0 on the y-axis indicates the value that represents the equal use of the affected 
and unaffected forelimb during spontaneous rearing. WT represents wild type animals 
and TG represents transgenic animals. Animal numbers are as follows: WT + saline 
(n=7), WT + stroke (n=8), TG + saline (n=8), TG + stroke (n=6). Values are presented as 
mean ± SEM. (Two-way ANOVA, Tukey post hoc).  
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Figure 11. Co-morbid rats take an increased number of steps during the beam-walk 
task. Errors were counted as hindlimb slips while walking across the beam for affected 
(A) and unaffected (B) hindlimbs. Difference in errors was calculated to normalize to 
baseline (day -7) values (post-surgery errors – pre-surgery errors). Total steps (C) 
required to cross the length of the beam. All values are an average of 6 trials per testing 
day. WT represents wild type animals and TG represents transgenic animals. Animal 
numbers are as follows: WT + saline (n=6), WT + stroke (n=6), TG + saline (n=6), TG + 
stroke (n=5). Values are presented as mean ± SEM and significance is annotated with an 
asterisks. (Two-way ANOVA, Tukey post hoc for hindlimb errors and p < 0.05, Two-
way ANOVA, Bonferroni post hoc for total steps).
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3.2.3 Spatial Reference Memory Deficit Present in the Co-morbid 
Condition 
Spatial learning was measured as the latency and distance to the reach the 
platform across 4 days of acquisition. For all groups there was a significant decrease in 
the latency to reach the platform observed (day 8 vs. day 11, p < 0.05, Figure 12A). This 
result was accompanied by a significant decrease in the distance to reach the platform 
over 4 days of spatial learning (day 8 vs. day 11, p < 0.05, Figure 12B). This suggests 
successful learning of the platform location by all surgical groups. Furthermore, there 
were no differences in learning between surgical groups, as there were no differences in 
the latency or distance to reach the platform between groups on each testing day (Figure 
12A-B). Swim speed was monitored to ensure that differences in time and distance were 
not a result of different swim speeds during testing and there were no differences in swim 
speed across groups on each testing day (Figure 12C).  
Spatial reference memory for the target zone that housed the hidden platform 
during spatial learning was measured as the latency to first entry into the target zone 
during probe testing. Short-term and long-term memory was assessed 24 hours after 
spatial learning (day 12) and 1 week after spatial learning (day 19), respectively. The 
swim speed during probe testing was monitored to ensure that differences in swim speed 
did not account for the difference in latency. While there were no differences across 
surgical groups on each testing day, the co-morbid group (transgenic + stroke) exhibited 
slower swim speeds on day 19 compared to day 12 (p < 0.05, data not shown). To 
account for the difference in speed, the latency to first enter into the target zone was 
standardized to a speed ratio for each individual rat on both testing days and is presented 
in Figure 13 as the standardized latency to first entry into the target zone. The co-morbid 
condition (transgenic + stroke) demonstrated a greater latency to first enter into the target 
zone across testing days (day 12 vs. day 19, p < 0.05, Figure 13). This effect indicates 
that the co-morbid condition induced long-term memory deficits, as the difference was 
not observed among other surgical groups representing each condition alone (Figure 13). 
Percent time in the target zone during probe testing was also analyzed, but was not 
significant between groups (data not shown).  
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Figure 12. Spatial learning of location of hidden platform in MWM. Spatial learning 
is represented as latency (A) and path length (B) to reach the platform across four 
consecutive days of learning. Swim speed (C) was monitored during spatial learning to 
ensure differences in latency and path length were not due to speed differences. WT 
represents wild type animals and TG represents transgenic animals. Animal numbers are 
as follows: WT + saline (n=8), WT + stroke (n=9), TG + saline (n=8), TG + stroke (n=8). 
All values are presented as mean ± SEM. (p<0.05, Two-way ANOVA, Tukey post hoc).
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Figure 13. Co-morbid transgenic animals with stroke demonstrate spatial reference 
memory deficits. Spatial reference memory is represented as the latency to first enter the 
target zone during probe testing on day 12 and 19. The target zone is the quadrant that 
housed the hidden platform during spatial learning. WT represents wild type animals and 
TG represents transgenic animals. Animal numbers are as follows: WT + saline (n=8), 
WT + stroke (n=9), TG + saline (n=8), TG + stroke (n=8). All values are presented as 
mean ± SEM and significance is represented with an asterisk. (p < 0.05, Two-way 
ANOVA, Bonferroni post hoc). 
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Cued learning was implemented to assess motivation to escape the pool and the 
ability to use spatial cues to locate a hidden platform. The latency and distance to reach 
the platform was measured and averaged over two days of learning. Additionally, swim 
speed was assessed and averaged across both testing days. The outcome indicates that 
there were no differences in motivation to escape the pool or the ability to use spatial 
cues, as the latency and distance to reach the platform was not significantly different 
between groups (Figure 14A-B). A potential difference in the latency and distance to 
reach the platform was not masked by differences in swim speed, as there were no 
differences in swim speed across all surgical groups (Figure 14C).  
3.2.4 Increased Presence of Activated Microglia in the Infarct Region 
Transgenic rats with stroke exhibited a significantly greater volume of activated 
microglia in the right striatum compared to their transgenic counterparts without stroke (p 
< 0.05, Figure 15E). Furthermore, transgenic + stroke rats tended to have a greater 
volume of microglia compared to wild type rats without stroke, but this effect was not 
significant (p = 0.0509, Figure 15E). Wild type rats with stroke did not demonstrate 
significantly greater levels of microglial inflammation within the infarct region compared 
to their wild type and transgenic counterparts without stroke (Figure 15E). The coupling 
of these results suggests that the co-morbid condition resulted in an exacerbated 
microglial inflammation volume in the right striatum. 
3.2.5 Activated Microglia Neuroinflammation in the Basal Forebrain 
Previously, Aβ toxicity alone induced a significant increase in activated microglia 
presence in the basal forebrain (Nell et al., 2014). Therefore, analysis of the effect of the 
co-morbidity of stroke and AD on microglia in the basal forebrain was conducted. Cell 
counts of activated microglia detected using the OX-6 antibody were quantified in the 
basal forebrain. There were no significant differences in the number of microglia present 
in the basal forebrain across surgical groups (Figure 16J). The co-morbid group 
(transgenic + stroke) tended to have greater levels of activated microglia compared to 
their wild type counter parts with or without stroke, but this effect was not significant (p 
= 0.0515 and p = 0.0889, Figure 16J). 
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Figure 14. MWM cued learning of a hidden platform with a visible cue attached. 
Latency (A) and path length (B) to reach the platform are represented as an average of all 
eight trials across two days of cued learning. Swim speed (C) is presented as an average 
of all eight trials across two days of cued learning. WT represents wild type animals and 
TG represents transgenic animals. Animal numbers are as follows: WT + saline (n=8), 
WT + stroke (n=9), TG + saline (n=8), TG + stroke (n=8). All values are presented as 
mean ± SEM. (One-way ANOVA, Tukey post hoc).
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Figure 15. Co-morbid transgenic animals with stroke demonsrate exacerbated 
microglial volume in the right striatum infarct area. (A-D) 2X photomicrographs of 
representative microglial inflammation in the right striatum. (E) Volume of right striatal 
inflammation based on the extent of OX-6 immunolabelled microglia. Volume was 
calculated using the following equation: [(ΣOX-6 inflammation surface area) x ({n-
1}{0.035}{0.315})] where n = number of OX-6 immunolabelled sections. Scale bar = 1 
mm. WT represents wild type animals and TG represents transgenic animals. Animal 
numbers are as follows: WT + saline (n=7), WT + stroke (n=7), TG + saline (n=6), TG + 
stroke (n=6). All values are presented as mean ± SEM and significance is annotated by an 
asterisk. (p < 0.05, One-way ANOVA, Tukey post hoc).
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Figure 16. Activated microglial presence in the basal forebrain. Representative 2X 
(A-D) and 10X (E-H) photomicrographs of microglia in the basal forebrain. Boxed areas 
in A-D represent the area in the 10X photomicrographs that accurately represented the 
mean microglial cell count for each group. (I) Atlas representation of rat brain with areas 
used in counting outlined with thick black lines. (J) Microglial cell counts of 10X 
photomicrographs of OX-6 immunolabelled basal forebrain sections. Scale bar in D = 1 
mm. Scale bar in H = 100 µm. WT represents wild type animals and TG represents 
transgenic animals. Animal numbers are as follows: WT + saline (n=7), WT + stroke 
(n=7), TG + saline (n=6), TG + stroke (n=6). All values are presented as mean ± SEM. 
(One-way ANOVA, Tukey post hoc). 
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Chapter 4: 
Discussion
  58 
 This study used two unique co-morbid rat models of stroke and AD to examine 
gross and fine motor changes, cognitive impairment and neuroinflammation. In the first 
study, stroke was paired with the intracerebroventricular Aβ toxicity model in six-month-
old Wistar rats. Previously, this had only been implemented in three-month-old rats 
(Amtul et al., 2014; Whitehead et al., 2005b; Whitehead et al., 2007). While there were 
no observed motor deficits, there were significant cognitive deficits related to spatial 
reference memory exhibited in the six-month-old co-morbid model. This cognitive deficit 
was not apparent in the control or stroke alone groups and was ameliorated when the co-
morbid group received CAT-SKL treatment. Previous studies have demonstrated the 
protective effect of CAT-SKL in in vitro (Giordano et al., 2014) and in vivo (Nell, 2013) 
models of Aβ toxicity. However, for the first time, this study demonstrated the 
effectiveness of CAT-SKL as a protective therapeutic agent against cognitive decline in a 
co-morbid animal model of stroke and Aβ toxicity. Previous studies investigating Aβ 
toxicity have suggested that neuroinflammation plays a key role in the pathogenesis of 
AD (Haga et al., 1989; Lue et al., 1996; Nell et al., 2014). One study observed an 
increased microglia neuroinflammatory response in the basal forebrain, an area of the 
brain implicated in the early stages of AD (Auld et al., 2002; Nell et al., 2014). In the 
present study, the co-morbid condition had significantly increased activated microglia in 
the basal forebrain that was attenuated upon treatment with CAT-SKL.  
 In the second series of experiments, a novel model was utilized in the 
investigation of the co-morbidity of stroke and AD. This is the first evidence of stroke 
inducing pathological cognitive decline and neuroinflammation in a hAPPSwe/Ind 
transgenic rat model that alone does not develop any pathological hallmarks of AD with 
age. The co-morbid group demonstrated early indication of potential gait disturbances in 
the beam-walk task, which has been considered an early and often overlooked symptom 
in AD (Sheridan and Hausdorff, 2007). Moreover, transgenic rats with stroke were the 
only group to exhibit deficits in hippocampal-dependent spatial reference memory in the 
MWM. Previous studies have postulated that increased levels of neuroinflammation are 
involved in the early stages of the pathogenesis of AD (Akiyama et al., 2000; Heneka et 
al., 2015; Wyss-Coray and Mucke, 2002). Furthermore, the exacerbation of microglia 
  59 
within the infarct region in a co-morbid stroke and Aβ toxicity rat model has been 
previously demonstrated (Hepburn, 2012; Whitehead et al., 2007). Immunohistochemical 
investigation of activated microglia demonstrated that the co-morbidity of stroke in the 
transgenic group resulted in increased levels of microglial neuroinflammation in the 
infarct region. 
4.1 Motor Assessment: Cylinder, Modified Sticky Tape and Beam-
walk Tasks 
In both co-morbid models, there was no evidence of forelimb gross motor deficits 
during spontaneous rearing in the cylinder task. This task has been widely implemented 
in research investigating various models of stroke. Clarke et al. (2007) demonstrated that 
APP transgenic rats with MCAO exhibit a significant decrease in the use of the affected 
forelimb for postural support during spontaneous rearing. Furthermore, a decrease in the 
use of the affected forelimb in an ET-1 induced cortical stroke model (Soleman et al., 
2010) and bilateral CCAO model has been previously observed (Choi et al., 2011). These 
stroke models involve relatively large regions of the cortex and would be expected to 
induce relatively gross contralateral motor deficits. To our knowledge, this task has never 
been implemented in the striatal stroke model.  
The striatum is a key structure in the basal ganglia, which also includes the globus 
pallidus, substantia nigra, thalamus and cortex. Through a series of connections, these 
structures regulate each other by sending and receiving signals and ultimately provide 
information to control motor movement (Groenewegen, 2003). In Parkinson’s patients, 
dysfunction of the basal ganglia results in the phenotypic inability to control motor 
movement. For example, the striatum receives aberrant signalling from the damaged 
neurons of the substantia nigra resulting in the disruption of this pathway and 
contributing to the inability to control motor movement (Ena et al., 2011; Moore et al., 
2010). While it is widely accepted that the striatum plays a role in motor control, the 
striatal lesion induced in both co-morbid models may be incapable of producing major 
gross motor deficits due to the relatively small size of the lesion. It is possible that with a 
longer timeline following stroke intervention or a larger stroke emcompassing more of 
the striatum, significant gross motor deficits would appear during forelimb use in both the 
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hAPPSwe/Ind transgenic model and the stroke and Aβ injection model. While the cylinder 
task is an effective paradigm for detecting motor deficits in previously mentioned stroke 
models, it is also possible that the location and size of the infarct is incapable of 
producing such motor deficits and no amount of time will influence the outcome. 
Investigation of fine motor and somatosensory function in the MST task produced 
similar results to the cylinder task. The co-morbid stroke and Aβ injection model did not 
develop fine motor or somatosensory deficits, as was the case with all of the other 
surgical groups. Sughrue et al. (2006) adapted the MST from the conventional sticky tape 
task in order to create testing that was more specific to focal unilateral damage and did 
not require pre-training. It has previously been demonstrated that rats with MCAO are 
significantly less attentive to tape on the affected forelimb compared to the unaffected 
forelimb (Komotar et al., 2007; Sughrue et al., 2006). This result was not replicated using 
the conventional sticky tape task in the same model (Sughrue et al., 2006). Moreover, it 
has previously been shown that rats with an ET-1 induced striatal stroke demonstrated 
impaired functional recovery during assessment with MST testing (Carodoso et al., 
2013).  
Exacerbation of fine motor deficits has been previously reported in co-morbid 
models of stroke and AD (Clarke et al., 2007; Whitehead et al., 2005a), but to our 
knowledge few studies have investigated the effect of co-morbidity on somatosensory 
function. The striatum receives inputs from and provides output to the somatosensory 
cortex in addition to the aforementioned connections. Previous evidence would suggest 
that disruption of these connections through lesions in the striatum might result in 
abnormal neuronal processing of and response to somatosensory stimuli (Carodoso et al., 
2013). Therefore, a co-morbid condition involving a striatal stroke could hypothetically 
result in exacerbated somatosensory deficits compared to a stroke alone condition. Often 
in clinical co-morbid cases of stroke and AD, patients experience infarcts that are on the 
level of “mini-strokes” and are essentially imperceptible (Vermeer et al., 2002; Smith et 
al., 2012). Upon repeat insult or over time, these strokes can eventually result in visible 
stroke-related symptoms in addition to exacerbated AD-related cognitive decline 
(Snowdon et al., Vermeer et al., 2007). As with the cylinder task, it is possible that the 
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infarct size induced in the stroke and Aβ injection model is not large enough to 
significantly impact the function of somatosensory processes. Additionally, there is no 
evidence from the present results suggesting that an increase in animal number will affect 
the overall result, but a longer timeline after induction of stroke may have a different 
effect.  
In the co-morbid hAPPSwe/Ind transgenic rat model with stroke, there were no 
significant motor deficits present in the affected or unaffected hindlimb when considering 
error rate alone. However, upon analysis of the total steps taken to cross the beam, co-
morbid hAPPSwe/Ind transgenic rats with stroke required a significantly greater number of 
steps to cross the beam post-stroke. Classically, the beam-walk task is used to evaluate 
motor deficit by quantifying the number of slips or falls that occur while walking across 
the beam (Schallert et al., 2002). Lipsanen et al. (2011) reported a significantly increased 
number of slips in a MCAO model compared to sham animals. Furthermore, a multi-
stroke model involving focal ischemia in the sensorimotor cortex and striatum 
demonstrated an increased number of errors following stroke (Clarke et al., 2009, Windle 
et al., 2006). While the co-morbid hAPPSwe/Ind transgenic model with stroke did not 
produce a motor deficit as defined by an increased number of errors, the significant 
difference in the number of steps may indicate potential gait disruption.  
Alterations in gait patterns and balance have been implicated as an early clinical 
indication of AD (Sheridan and Hausdorff, 2007). Visser (1983) demonstrated that AD 
patients had significantly shorter step length, lower gait speed, lower stepping frequency, 
greater step-to-step variability, greater double support ratio and greater sway path 
compared to their age- and sex-matched controls. Furthermore, patients with AD and 
cerebrovascular disease have impaired gait and balance compared to their AD 
counterparts without cerebrovascular disease (Inzitari et al., 2013). The co-morbid 
hAPPSwe/Ind transgenic rat model with stroke had a stroke induced in the striatum and 
stroke is a form of cerebrovascular disease. Specifically, the striatum and other basal 
ganglia structures are involved in balance and walking in addition to the aforementioned 
functions (Sheridan and Hausdorff, 2007). The coupling of previous evidence with the 
potential gait alterations highlighted in the beam-walk task, it is possible that the co-
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morbid hAPPSwe/Ind transgenic rat model developed gait or balance abnormalities as a 
result of the co-morbidity. Additional studies using gait-specific motor tasks would be 
required to confirm this speculation in the current model and are highly suggested for 
future research investigating the early stages of AD pathogenesis.  
4.2 Development of Cognitive Decline in Co-morbid Models of Stroke 
and AD 
Spatial learning in the MWM provided no evidence for differences in the ability 
to learn the location of the hidden platform for either the stroke and Aβ injection or the 
hAPPSwe/Ind transgenic model. In both studies, all groups learned the task to the same 
extent, as demonstrated by the lack of differences between groups for the latency and 
distance to reach the platform. However, Choi et al. (2011) previously reported the 
development of spatial learning deficits in a co-morbid Aβ25-35 injection and bilateral 
CCAO model in the MWM. Deficits in spatial learning have also been demonstrated 
following intervention with Aβ peptide in rats (Zussy et al., 2013) and in transgenic 
rodent models of AD (Kloskowska et al., 2010). The inconsistency between these studies 
and the current studies may be explained by various differences in the animal model and 
behavioural timeline. The behavioural paradigm implemented here started MWM spatial 
learning one week following surgical intervention, whereas the aforementioned studies 
used various start points that were later than one week following intervention. 
Furthermore, Zussy et al. (2011) reported a time-course difference in spatial learning, 
whereby spatial learning deficits were not present until three weeks following Aβ surgical 
intervention. Therefore, the one-week timeline between surgical intervention and the 
beginning of MWM spatial learning may not have been an adequate amount of time to 
develop co-morbid or Aβ-induced learning deficits. 
Regarding the variability between animal models and learning, it has been 
described that the aggregation state of Aβ upon injection influences spatial learning 
abilities. Delobette et al. (1997) reported that the injection of aggregated Aβ25-35 
significantly increased the latency to reach the platform, which is indicative of a spatial 
learning deficit. Moreover, injection of soluble Aβ25-35 did not result in the same effect 
and demonstrated equal spatial learning abilities to the control group by the end of spatial 
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learning (Delobette et al., 1997). Spatial learning impairments demonstrated in transgenic 
models of AD are often present in models that inevitably develop amyloid plaques and 
significant cognitive deficit with age (Cohen et al., 2013; Leon et al., 2010; Nalbantoglu 
et al., 1997). The hAPPSwe/Ind transgenic rat model utilized in the present study does not 
develop amyloid plaques or cognitive deficits with age alone. This model is likely unable 
to produce significant spatial learning deficits on account of the lack of age-related 
amyloid accumulation, as demonstrated in other transgenic rodent models that develop 
learning deficits.  
In the instance of co-morbid models with spatial learning deficits, the 
aforementioned bilateral CCAO model is a stroke model with extensive cortical damage 
(Choi et al., 2011) compared to the ET-1 striatal stroke model in the experiments 
described here. It is possible that due to the smaller size and location of the stroke, the co-
morbid interaction is not large enough to induce learning impairments. The discrepancy 
between these studies and this thesis is not a cause for major concern, as differences in 
learning may account for differences in subsequent spatial reference memory.  
While cued learning was primarily used here as a control for the ability to use 
spatial cues to locate the platform and motivation to escape the pool, it has been 
previously demonstrated that cued learning can be affected by lesions in the striatum 
(Lovinger, 2010). Specifically, the striatum has been shown to be involved in learning 
and memory processes, such as skill learning, response-based learning and goal-directed 
learning (Lovinger, 2010). Packard and Teather (1997) previously demonstrated that 
administration of an NMDA receptor antagonist in the striatum after completion of eight 
training trials impaired retention of the cued learning task 24 hours after the initial 
training. For both co-morbid models, there were no differences in cued learning based on 
the latency and distance to reach the platform after two days of learning. This indicates 
that the infarct in the striatum did not induce a memory impairment of the cued learning 
task 24 hours after the first day of learning. It is possible that the damage in the striatum 
in both of these models is not significant enough to impair learning and memory in the 
cued task. Furthermore, this allows us to be confident that any significant differences 
demonstrated in other aspects of MWM were not due to deficits in striatal participation in 
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learning and memory, but the result of the co-morbid condition on other areas associated 
with learning and memory. 
The results of these experiments did demonstrate that long-term spatial reference 
memory following spatial learning in the MWM was impaired in both co-morbid models 
of stroke and AD. This effect was strictly due to the co-morbidity of the two diseases, as 
the striatal stroke, Aβ injection or transgenic background alone did not induce the same 
impairment. Previous studies have associated the co-morbid condition with exacerbated 
behavioural pathology and evidence of the interaction clinically has been well described 
(Kalaria, 2000; Levine et al., 2015; Vermeer et al., 2007; Whitehead et al., 2007). 
Clinically, Snowdon et al. (1997) reported that in a controlled population, the co-
morbidity of small striatal strokes and AD resulted in a more progressed level of 
cognitive impairment compared to their AD counterparts. Furthermore, animal studies 
have demonstrated significant memory deficit in Aβ injection (Nell et al., 2014), 
transgenic rodent (Cohen et al., 2013; Hsiao et al., 1996) and co-morbid models of AD 
(Cechetto et al., 2008). The stroke and Aβ injection model and hAPPSwe/Ind transgenic 
model with stroke results are in accordance with previously described findings, but this is 
the first time that significant cognitive impairment has been reported in these unique 
models. Additionally, most behavioural studies have been conducted in three-month-old 
rats (Amtul et al., 2014; Leon et al., 2010; Whitehead et al., 2007) and to our knowledge 
this is the first evidence of exacerbated cognitive impairment in a more appropriately 
aged model in relation to the clinical onset of AD. The memory impairment observed in 
these two models further emphasizes the importance of expanding our understanding of 
the interaction of these two diseases and the inevitable advanced decline that 
accompanies the co-morbid condition. 
4.3 Stroke Pathology: Activated Microglia Presence in the Striatum 
The volume of activated microglia in the striatal infarct region did not differ 
between groups in the stroke and Aβ injection model. However, exacerbated microglia in 
the striatum of the co-morbid hAPPSwe/Ind transgenic with stroke group compared to its 
saline counterparts was observed. There is substantial evidence implicating aberrant 
microglial presence in the early stages of AD (Nell et al., 2014; Wyss-Coray and Mucke, 
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2002) and microglia are an important factor in post-stroke repair mechanisms (Lakhan et 
al., 2009; Wang et al., 2007). Whitehead et al. (2007) previously reported increased 
volume of microglia in the striatum of rats with striatal stroke and Aβ25-35 injections 
compared to striatal stroke alone. Various other studies have also demonstrated this effect 
in stroke and Aβ co-morbid conditions with varied concentrations of ET-1 and Aβ 
(Amtul et al., 2014; Hepburn, 2012). Moreover, increased infarct volume measured as the 
extent of neurodegeneration in a co-morbid stroke and Aβ model further supports the 
notion that the co-morbid condition results in exasperated stroke pathology (Amtul et al., 
2014; Caughlin et al., 2015).  
The aforementioned studies investigating the neuroinflammatory and 
neurodegenerative outcome in the infarct region of co-morbid models were completed in 
three-month-old Wistar rats (Amtul et al., 2014; Caughlin et al., 2015; Whitehead et al., 
2007). Inflammation is believed to undergo progressive changes with age, whereby the 
level of inflammatory mediators throughout the body is greater in healthy older 
individuals (Godbout and Johnson, 2009). The age-related increase in inflammatory 
meditors may render the brain vulnerable to drastic alterations in neuroinflammation. 
Therefore, when age-related inflammatory changes are coupled with brain injury, the 
brain may quickly succumb to an aberrant neuroinflammatory response. In the current 
study, the stroke and Aβ injection model was completed in six-month-old Wistar rats. It 
is feasible that the level of neuroinflammation demonstrated in this model is relatively 
maximized in the anatomical confines of the striatum in the six-month-old rat. However, 
further investigation of the time-course of the inflammatory response to stroke would 
need to be completed to confirm this possibility. This does not devalue the development 
of cognitive impairment in the co-morbid condition, as it is highly possible that the co-
morbid condition is still causing exacerbated consequences in downstream targets.  
While the hAPPSwe/Ind transgenic rats were also six months of age, the co-morbid 
group demonstrated increased microglia in the striatal infarct region. The hAPPSwe/Ind 
transgenic rat model is on a different genetic background than the stroke and Aβ injection 
model and thus cannot be directly compared. However, when comparing the volume of 
microglia within the striatum between strains, the APP transgenic rats appear to have less 
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microglial volume in the striatum compared to the Wistar rats. Regardless of the 
differences between the models, the increased volume of neuroinflammation in the 
striatum of hAPPSwe/Ind transgenic rats with stroke further confirms the effect of the co-
morbidity on stroke pathology. Additionally, it has previously been demonstrated that co-
morbid rats demonstrate increased levels of neuroinflammation and greater motor 
impairments in the staircase task (Whitehead et al., 2005a). Previous studies and the 
exacerbated striatal neuroinflammation combined with the potential motor deficits 
observed in the beam-walk task suggests that microglia may contribute to the 
development of pathological behavioural changes in the co-morbid hAPPSwe/Ind transgenic 
rat model.  
4.4 Neuroinflammation in the Basal Forebrain 
Measuring the extent of microgliosis in the basal forebrain showed a significant 
response to the co-morbid condition in the stroke and Aβ injection model. In response to 
striatal stroke and Aβ25-35, there was an exacerbated level of microglia present in the basal 
forebrain, which is a key brain structure involved in the pathogenesis of AD (Auld et al., 
2002). A significant increase in activated microglia was not demonstrated in the 
hAPPSwe/Ind transgenic model with stroke. However, the co-morbid hAPPSwe/Ind transgenic 
with stroke group certainly showed a trend in greater levels of microglia in the basal 
forebrain compared to their wild type counterparts and a longer timeline or a larger stroke 
may have resulted in significance.  
The basal forebrain is considered one of the earliest structures affected in the 
pathogenesis of AD (Auld et al., 2002). Structures within the basal forebrain are an 
integral part of the cholinergic system and send projections to the hippocampus and 
neocortex, two brain structures largely implicated in learning and memory (Auld et al., 
2002; D’Hooge and Deyn, 2001; Schliebs, 2005). The damaging properties of aberrant 
neuroinflammation in neurodegenerative diseases are evident throughout the literature 
(Akiyama et al., 2000; Latta et al., 2014; Wyss-Coray and Mucke, 2002). In the basal 
forebrain specifically, it is possible that the extensive microglial presence contributes to 
the chronic hypofunction of cholinergic neurons in the basal forebrain in AD patients 
(Auld et al., 2002; Schliebs and Arendt, 2011). Previously, administration of Aβ1-40 
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induced a significant increase in microglia in the basal forebrain (Scali et al., 1999). Nell 
et al. (2014) also reported significant microgliosis along with a corresponding decrease in 
the number of cholinergic neurons in the basal forebrain in six-month-old rats receiving 
Aβ25-35. Combined with previous evidence, the increased level of microgliosis 
demonstrated in the stroke and Aβ injection model suggests that neuroinflammation plays 
a major role in the damaging interaction of this co-morbid condition. 
In addition to neuroinflammation, there are various cellular and metabolic 
changes and brain structures involved in the pathogenesis of AD that interact to cause the 
development of the characteristic symptoms. While the role of neuroinflammation in AD 
has been widely investigated and is considered to play a major role in the early stages of 
the disease, it is not the only factor involved (Butterfield et al., 2001; Huang and Mucke, 
2012; Querfurth and LaFerla, 2010). The co-morbid hAPPSwe/Ind transgenic with stroke 
model may not have demonstrated significant increases in microglia in the basal 
forebrain, but there was evidence that this was beginning to appear. It is possible that 
other factors may be mediating the behavioural deficits demonstrated, such as oxidative 
stress, Aβ deposition, among other elements. On the contrary, the trend in exacerbated 
inflammation suggests that the co-morbid condition in the hAPPSwe/Ind transgenic rat 
model may have developed microgliosis in the basal forebrain at a later time point. 
Studies in other transgenic rodent models of AD have demonstrated significant microglia 
presence in a brain devoid of amyloid plaques (Ferretti and Cuello, 2011; Hanzel et al., 
2014). Therefore, transgenic backgrounds are still able to initiate a neuroinflammatory 
cascade in response to insult, foreign pathogens or Aβ. Furthermore, evidence of 
increased levels of microglia in the infarct region of this co-morbid model also supports 
the role of neuroinflammation in the development of exacerbated pathologies in the co-
morbid condition.  
4.5 Effectiveness of CAT-SKL as a Therapeutic Mechanism 
In the stroke and Aβ injection model, the use of the targeted antioxidant CAT-
SKL as a treatment in the co-morbid condition was investigated. In the current 
experiment, CAT-SKL was able to effectively ameliorate cognitive decline as a result of 
the co-morbid condition. Furthermore, treatment with CAT-SKL decreased the levels of 
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microglia in the basal forebrain to control levels suggesting that inflammation was 
involved in mediating the cognitive decline in the co-morbid condition. This is the first 
evidence of CAT-SKL reducing the behavioural and cellular pathologies resulting from 
the toxic interaction that occurs in the co-morbid condition. Coupled with studies 
investigating the protective effects of CAT-SKL in vitro and in vivo, these results further 
support the role of oxidative stress and H2O2 in mediating cellular damage and 
neuroinflammation in injury and neurodegeneration (Giordano et al., 2014; Nell, 2013). 
Several studies investigating the effect of CAT-SKL on various injury and disease 
models have been completed. Undyala et al. (2011) demonstrated that pre-treatment of 
cultured rat cardiac myocytes with CAT-SKL resulted in decreased levels of H2O2. 
Furthermore, investigation of cardiac myocyte cell viability showed that CAT-SKL was 
protective against hypoxia and ischemia reperfusion injury (Undyala et al., 2011). 
Giordano et al. (2014) reported that treatment of cultured rat primary cortical and 
hippocampal neurons with CAT-SKL decreased ADDL-induced oxidative stress. This 
study also reported that treatment with CAT-SKL prior and subsequent to ADDL 
exposure resulted in decreased ADDL-induced neurotoxicity and neurite degeneration, 
implicating CAT-SKL as a preventative and therapeutic treatment. Nell (2013) reported 
that the cellular and behavioural pathological consequences of Aβ25-35 toxicity in vivo 
were attenuated by CAT-SKL treatment. This previous evidence along with the evidence 
presented in the co-morbid stroke and Aβ injection model in the present experiments 
suggests that H2O2 and oxidative stress play an important role in mediating cellular 
degeneration and neuroinflammation and that CAT-SKL may be an effective means of 
ameliorating this component leading to an improved outcome in several conditions. 
In accordance with prior research demonstrating that catalase levels in the brain 
decrease with age (Alper et al., 1998; Venkateshappa et al., 2012), catalase activity in the 
rat brain has been shown to begin to decrease in three-month-old rats (Sandhu and 
Gurcharan, 2002). This suggests that our six-month-old rat model may be vulnerable to 
elevated levels of oxidative stress due to decreased breakdown of H2O2 by catalase prior 
to surgical intervention. Furthermore, there is a large amount of evidence demonstrating 
that increased ROS production occurs prior and subsequent to Aβ toxicity (Aliev et al., 
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2003; Resende et al., 2008; Nunomura et al., 2000; Tabner et al., 2005). In particular, 
studies investigating levels of H2O2 specifically have shown increased levels of H2O2 in 
response to Aβ in vitro and in vitro (Behl et al., 1994; Kaminsky and Kosenko, 2008). 
Thus, the beneficial effect of CAT-SKL is likely due to its enzymatic degradation of 
H2O2 abolishing the ability for H2O2 to react with other molecules to produce highly toxic 
ROS. Furthermore, H2O2 and ROS can initiate a neuroinflammatory response resulting in 
activation of microglia and activated neuroinflammatory cells in turn release ROS 
(Akiyama et al., 2000; Hensley, 2010). Previously, CAT-SKL has been shown to 
attenuate Aβ-induced cholinergic loss and neuroinflammation in the basal forebrain with 
the subsequent attenuation of memory deficits (Nell, 2013). The interaction between 
oxidative stress and neuroinflammation contributes to a vicious cycle conducive to 
producing uncontrolled and damaging levels of ROS and neuroinflammation. 
Considering these relationships and effectiveness of CAT-SKL, a proposed 
mechanism of how CAT-SKL exerts its beneficial effects on cognitive decline and 
cellular pathology in a co-morbid model of stroke and AD can be suggested. It is 
probable that CAT-SKL results in the decrease of H2O2 with the subsequent decrease in 
ROS production resulting from stroke and Aβ toxicity. This decrease in oxidative stress 
in turn results in a decrease in the activation of microglia, which is upregulated in the co-
morbid stroke and Aβ condition. Thus, memory deficit induced by the co-morbid 
condition is attenuated owing to less damage to the basal forebrain due to aberrant levels 
of microglia and ROS. It is interesting to note that previous studies using anti-
inflammatory treatments in a co-morbid stroke and AD model were successful in 
ameliorating some of the pathology or cognitive deficits in either stroke or AD alone, but 
not the interaction between the two conditions, suggesting that neuroinflammation is not 
the only contributing factor in the pathogenesis of the co-morbid condition (Whitehead et 
al., 2005a). This theory is purely speculative and requires further investigation of a 
myriad of other factors, but the current and previous evidence of the effectiveness of the 
targeted antioxidant CAT-SKL strongly suggests that the interaction of 
neuroinflammation and oxidative stress is contributing to the pathological consequences 
of the co-morbid condition. 
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4.6 Limitations and Future Directions 
The studies presented are not without their limitations regarding models, timelines 
and dosages. In the stroke and Aβ injection model, the Aβ25-35 peptide is used to exert 
toxicity rather than the full length Aβ42. The full length Aβ42 is considered the canonical 
peptide in AD that has toxic and aggregative properties (Jarrett et al., 1993; Walsh and 
Selkoe, 2007; Querfurth and LaFerla, 2010). However, Aβ25-35 fragments have been 
found in brains of AD patients, but not in age-matched controls (Kubo et al., 2002). 
Previous studies of the effects of Aβ25-35 have demonstrated that the shorter length 
peptide is still capable of producing AD-like cellular and behavioural pathology in vivo 
(Amtul et al., 2014; Cheng et al., 2006; Nell et al., 2014; Whitehead et al., 2007). 
Furthermore, Aβ25-35 has been implicated as the neurotoxic core of the full-length peptide 
and retains the aggregation properties of Aβ42 (Pike et al., 1995; Yankner et al., 1989). In 
addition to its toxic properties, Aβ25-35 is more soluble than Aβ42 allowing for better 
diffusion into the brain upon injection (Kowall et al., 1992; Millucci et al., 2009). AD is a 
complicated disease with an intertwining web of cellular factors resulting in the 
inevitable neurodegeneration and modeling the disease, as a whole remains difficult. 
While this limitation is evident, the use of Aβ25-35 in rodent models is equal in its 
effectiveness and easier to use compared to Aβ42 and provides extremely important 
information regarding key aspects involved in the pathogenesis of AD-like pathologies 
and the stroke co-morbid condition. Future studies should seek to replicate the results of 
this model in a rodent model with the ability to produce the full length Aβ42 peptide or 
Aβ oligomers.  
AD is considered a highly progressive neurodegenerative disease with various 
stages of cognitive decline (Karran et al., 2011; Schliebs and Arendt; 2011; Selkoe, 
2001). While the goal of these studies were to investigate the early cellular and 
behavioural implications involved in the pathogenesis of the disease, the twenty-one day 
timeline only provides a snapshot of changing pathologies in a progressive disease. To 
enhance our understanding of the overall contribution of neuroinflammation and 
oxidative stress in the pathogenesis and progression of AD, future studies must be 
completed at earlier and later time frames. Furthermore, studies encompassing numerous 
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time points will provide a better understanding of the time course involved in the co-
morbid condition. For example, understanding when the brain is most vulnerable to 
stroke injury and what downstream brain structures are particularly vulnerable to striatal 
strokes at different stages of the disease may be helpful in highlighting therapeutic targets 
in the co-morbid condition.  
The present study in the stroke and Aβ injection model also effectively 
demonstrated the therapeutic potential of the targeted antioxidant CAT-SKL. Dosages 
and treatment timelines were based on successful therapeutic effect in previous in vivo 
studies (Nell, 2013). However, many questions remain regarding the therapeutic 
mechanism, pharmacological properties and its effect on other cellular outcomes in the 
co-morbid condition. Further investigation into the levels of ROS, oxidative damage and 
catalase levels are required to determine whether CAT-SKL exerts its antioxidant 
properties by directly abolishing ROS production or indirectly by increasing levels of 
endogenous catalase. Examination of these aspects will also elucidate the potential 
therapeutic mechanism behind CAT-SKL. This study was the first time CAT-SKL was 
used as a treatment in the stroke and Aβ co-morbid condition. The results of this study 
provided crucial information about the interaction in the co-morbid condition and are 
useful in guiding future use of CAT-SKL and other antioxidants as therapeutic 
treatments. However, continual use of CAT-SKL in future studies warrants investigation 
into the aforementioned aspects to gain a more comprehensive understanding of the 
interaction of the co-morbid condition and the mechanism of CAT-SKL. 
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Chapter 5: 
Summary and Conclusions
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This thesis has presented considerable evidence indicating that there is 
exacerbated memory loss in the co-morbid stroke and AD condition. It has also been 
previously demonstrated that motor deficits can be exacerbated by the interaction of these 
two diseases in a co-morbid animal model (Whitehead et al., 2005a). The present results 
support this idea by the presence of gait-related motor disturbances in the co-morbid 
hAPPSwe/Ind transgenic rats with stroke. While the focus of this study was investigating 
the cognitive impact of the co-morbid condition, as observed in the MWM as a memory 
deficit in both co-morbid models, the results reported also implicate the potential role of 
microglia in the early stages of cognitive decline associated with AD and stroke. 
Furthermore, aspects of this study have provided evidence for the use of targeted 
antioxidants as potential therapeutic mechanisms for further treatment of AD and its co-
morbidity with stroke and possibly other vascular pathologies.  
To our knowledge, this is the first time that the co-morbid condition has been 
demonstrated in an older animal model. Previous studies often induced Aβ toxicity or a 
co-morbid disease state in three-month-old rats (Amtul et al., 2014; Caughlin et al., 2015; 
Cheng et al., 2006; Whitehead et al., 2007). The leading risk factor for sporadic forms of 
AD is age and Nell et al. (2014) demonstrated that older six-month-old animals 
demonstrate higher levels of Aβ-induced neuroinflammation and cholinergic loss 
accompanied by the characteristic memory loss associated with AD. Both the stroke and 
Aβ injection model and the hAPPSwe/Ind transgenic rat model with stroke demonstrated 
significant memory impairment in the MWM at six months of age. This is also the first 
time that stroke has been shown to induce AD-related memory deficits in a hAPPSwe/Ind 
transgenic rat model that does not develop the AD-related memory deficits, amyloid 
plaques or neurofibrillary tangles with age alone.  
There was an exacerbation of microglial neuroinflammation in the basal forebrain 
of the co-morbid stroke and Aβ group and in the infarct region of the hAPPSwe/Ind 
transgenic group with stroke. This suggests that the neuroinflammatory response may be 
a key component in the pathogenesis of AD behavioural pathologies and the interaction 
of the co-morbid condition. Neuroinflammation has been previously implicated in the 
disease progression of AD, as well as in post-stroke tissue repair, and it is widely 
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accepted as a key component in the early stages of cognitive decline in AD (Akiyama et 
al., 2000; Lakhan et al., 2009; Wyss-Coray and Mucke, 2002). This study further 
implicates the role of neuroinflammation in contributing to cognitive deficit, as increased 
levels of microglia were observed in the basal forebrain. This area of the brain is known 
to be vulnerable to AD-related neurodegeneration and contribute to learning and memory 
directly and indirectly through projections to the hippocampus (Auld et al., 2002; 
Schliebs and Arendt, 2011)   
While neuroinflammation has a major role in the pathogenesis of AD and repair 
of damaged tissue post-stroke, it is not the only factor at play in these two diseases. This 
study uses the targeted antioxidant CAT-SKL as a treatment in the co-morbid condition. 
Its effectiveness at ameliorating memory deficits and neuroinflammation in the basal 
forebrain in the stroke and Aβ injection model supports the role of oxidative stress in the 
network of factors involved in the co-morbid condition. Although oxidative stress alone 
likely cannot produce the level of damage that results in AD and post-stroke injury, 
evidence suggests that it is a key component in the disease process of both conditions and 
the co-morbid condition (Allen and Bayraktutan, 2009; Akiyama et al., 2000; Butterfield 
et al., 2001). The self-propagating relationship of oxidative stress with 
neuroinflammation, in addition to the relationship of Aβ with both of these cellular 
processes, underlies the importance of preventing or treating aberrant levels of oxidative 
stress. Furthermore, evidence of the beneficial effect of CAT-SKL supports further 
investigation into the maintaining the balance of ROS and antioxidants in diseased states 
and the use of CAT-SKL or other targeted antioxidants in the treatment of stroke, AD and 
the co-morbid condition.   
Lastly, the models used demonstrate early AD cellular and behavioural pathology 
and CAT-SKL demonstrated a therapeutic effect in one model, suggesting that these 
models can be effectively used to assess the early stages of stroke and AD pathogenesis 
and therapeutic agents that might be capable of interrupting the interaction between 
stroke and early AD pathology, subsequently preventing further decline. It is likely that it 
will be far easier to design therapeutic approaches that can prevent or slow the onset or 
reduce the frequency of conversion to the late stages of AD than it will be to treat the 
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fully expressed late-stage disease (i.e. amyloid plaques and neurofibrillary tangles). For 
that reason, these models can offer a great advantage in that they replicate the beginning 
of motor and cognitive decline due to the co-morbid conditions that are prevalent in the 
human population.
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